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mouse model to interrogate how TLR9, the primary sensing molecule for vector DNA, can activate cytotoxic
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(IDUA). We report that TLR9 signaling is also instrumental for the formation of anti-IDUA antibodies, as is
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peptide located downstream of a PTC can be induced. This insight can help us better define the risks
associated with an adaptive immune response based on an individual’s personal mutation. We also defined
important vector factors which are important for activation of an adaptive immune response, and this
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ABSTRACT 
IMPACT OF HOST FACTORS ON THE ADAPTIVE IMMUNE RESPONSE TO 
AAV GENE THERAPY 
Scott Ashley 
James Wilson 
Adaptive immune responses to the transgene product remain an active area of concern for 
the gene therapy field.  How host factors can influence the activation of the immune 
system is an important consideration in the development of gene therapy for different 
genetic disorders.  One factor considered by many to shape the adaptive immune 
response is an individual’s genotype.  Nonsense mutations were thought to result in an 
absence of tolerance to a replacement protein provided by gene therapy, due to a lack of 
antigen presentation during T cell development and negative selection.  In this work we 
demonstrated that a class of nonsense mutations, premature termination codons (PTC), 
found in ornithine transcarbamylase deficiency (OTC) patients do not inhibit antigen 
presentation of C-terminal epitopes.  We further found that these PTC containing OTC 
genes were able to induce anergy in a model of peripheral tolerance.  These results 
change how we think about the relationship between the genotype and immune response, 
which indicate that individuals with PTC mutations may be less at risk of an adverse 
immune response attenuating the effects of gene therapy.  We also identified vector 
factors that influence the adaptive immune response, activation of TLR9 and the tissues 
targeted for transduction and expression of the transgene.  To investigate how 
inflammatory signaling might impact the outcome of adaptive immune responses; we use 
 vii   
the transgenic OT-1 mouse model to interrogate how TLR9, the primary sensing 
molecule for vector DNA, can activate cytotoxic T cells against the transgene product 
OTC.  These results confirm an important role for TLR9 induced inflammation being 
necessary for transgene specific T cell activation.  To investigate the influence of TLR9 
signaling and tissue targets on the humoral response, we used a mouse model of 
Mucopolysaccharidosis type I (MPS1) disease, and measured antibody generation to the 
secreted transgene product alpha-L-iduronidase (IDUA).  We report that TLR9 signaling 
is also instrumental for the formation of anti-IDUA antibodies, as is expression of the 
transgene from the muscle.  This work describes a novel process by which tolerance to a 
peptide located downstream of a PTC can be induced.  This insight can help us better 
define the risks associated with an adaptive immune response based on an individual’s 
personal mutation.  We also defined important vector factors which are important for 
activation of an adaptive immune response, and this knowledge could be exploited to 
generate safer gene therapy delivery methods.   
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Chapter 1: Introduction 
Gene Therapy 
Gene therapy is a therapeutic approach designed to treat a wide variety of diseases by 
delivery of genetic material.  There are many different methods that fall under this 
umbrella including, but not limited to, delivery of a gene to replace a defective gene 
(Nathwani, Reiss et al. 2014), direct editing of the genome to correct an error (Yang, 
Wang et al. 2016), delivery of a gene to produce a therapeutic protein agent such as an 
antibody (Limberis, Adam et al. 2013), delivery of RNA or DNA to down regulated 
expression of an endogenous protein (Fitzgerald, Frank-Kamenetsky et al. 2014).  The 
most straight forward and explored application is the delivery of a gene by a viral vector 
to correct a monogenetic disorder.  This type of gene therapy has its origins in protein 
replacement, where individuals are given enzyme to replace a defective or missing 
protein.  However, protein replacement can have limits such as cost, constant re-
administration, and trafficking of the enzyme to proper target cells.  One application of 
gene therapy is the promise of a single dose cure that would allow the body to constantly 
replace the enzyme instead of requiring continuous re-infusions.   Vector design can also 
lead to targeted delivery of the gene allowing for the enzyme to be delivered to its proper 
location.  As an early example of this potential we can look to organ transplant, 
particularly of the liver, where the transplanted organ, containing the corrected gene, 
produces the missing protein for the rest of the individual’s life (Starzl, Bilheimer et al. 
1984).   It is for these disorders that gene therapy is making strides in bringing a better 
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standard of care (Naldini 2015).  For many genetic disorders, however only palliative 
care is available and the promise of gene therapy could enable individuals facing difficult 
challenges the opportunity to live a longer with an improved quality life. 
Viral Vectors and Immunology 
One theme in the development of gene therapy for monogenic diseases has been the 
obstacle that a patient’s own immune system can present.  Two types of immune 
responses can occur, one is innate immunity driven by myeloid lineage leukocytes that 
primarily respond to generic non-self-patterns often found in pathogens including non-
nuclear un-methylated DNA, double stranded RNA, or lipopolysaccharide.  The other 
immune response is adaptive and has the ability to target specific diseases by recognizing 
either small peptide sequences or the three dimensional structure of large 
macromolecules.  Gene therapy attempts to deliver a corrected gene that will express a 
protein. The body can potentially recognize that protein, the transgene product, as a 
foreign or “non-self” entity.  When this occurs the adaptive immune response develops 
specifically targeting both the transgene product and the cells that produce it (Mendell, 
Campbell et al.).  Adaptive immune responses that are able to recognize self-antigens 
from non-self-proteins are divided into two branches, the humoral, comprised of B cells, 
and the cytotoxic, mediated by T cells.  Both these lymphocytes lineages undergo a 
maturation that will remove T and B cells which recognize self-antigen from the 
population by mechanisms of clonal deletion in a process known as central tolerance 
(Kappler, Roehm et al. 1987, Pelanda and Torres 2012).  These safeguards however can 
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be incomplete as self-reactive T and B cell do escape the thymus and bone marrow 
respectively and can cause a disease state of auto-immunity where the cells activate 
against self-tissue (Yurasov, Wardemann et al. 2005, Meffre 2011, Pobezinsky, Angelov 
et al. 2012).  Another level of tolerance exists that helps mitigate the potential damage 
self-reactive T and B cells can inflict.  Peripheral tolerance involves many mechanisms to 
keep naïve self-reactive lymphocytes from becoming fully active, including a) ignorance, 
where the lymphocyte will have highly diminished contact with its specific antigen 
mostly occurring in so called immune-privileged regions such as the eye, brain, and testes 
(Streilein, Takeuchi et al. 1997) b) anergy, a state of non-responsiveness that occurs when 
antigen is presented to the lymphocyte without the secondary signal provided by co-
stimulation necessary to initiate T cell activation (Schwartz 2003) or c)  induced by direct 
suppression of the auto-reactive lymphocytes by regulatory cells (Lim, Hillsamer et al. 
2005, von Boehmer 2005).  While peripheral tolerance is difficult to overcome it can 
occur when danger or inflammatory signaling occurs, such as during infection, tissue 
damage, or cellular stress (Lang, Georgiev et al. 2006, Zhang, Shen et al. 2006, Ferrero-
Miliani, Nielsen et al. 2007).  These processes are important in understanding the 
difficulties imposed by the immune system on gene therapy.  Many patients that would 
receive gene therapy do not express the protein at all due to a “null” mutation caused by 
nonsense mutations, frameshifts, large deletions or chromosomal rearrangements.  This 
would increase the risk of an adverse reaction as no antigen would be presented during 
central tolerance allowing for a pool of potentially high affinity lymphocytes to exist 
(Naeher, Daniels et al. 2007).   For patients that do express non- or low- functioning 
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protein it is believed they are at less risk to develop a transgene immune response 
because lymphocytes should still undergo central tolerance, however escaped cells could 
still react if enough inflammatory signaling occurs around the time of vector expression.  
These signals can be caused by the vector itself and potentially by the transgene product 
or the protein of replacement (Rogers, Martino et al. 2011). 
Development of Viral Vectors 
Delivery of therapeutic genetic material into diseased cells is one of the critical aspects of 
consideration in gene therapy.  In the early days of the field, adenoviral vectors were used 
to package DNA and deliver it to the nucleus of infected cells.  These vectors, however, 
were phased out of use for treatment of genetic disorders, despite positive aspects such as 
a large gene capacity and high transduction efficiency, since they were found to induce 
robust immune responses (Bessis, GarciaCozar et al. 0000, Chen, Murphy et al. 0000).  
Early observations of the enhanced immune responses were found in the transduction of 
mouse liver with E1 and E3 deleted adenoviral vector expressing LacZ in immune 
competent CBA mice which cleared both expression of the transgene and genome copies, 
whereas immune compromised nude mice that lack T cells due to loss of proper thymus 
development maintained expression throughout the duration of the study (Yang, Nunes et 
al. 1994).  Expression of adenoviral proteins by the vector was found to be a major 
immunogenic stimulus that resulted in the observed destructive CTL response (Yang, 
Jooss et al. 1996).  These findings resulted in the rational design of the adenoviral vector 
by removing both the E1 and E4 regions of the genome to produce a less immunogenic 
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vector capable of long term stable expression in mice (Gao, Yang et al. 1996, Dedieu, 
Vigne et al. 1997, Wang, Greenburg et al. 1997, Christ, Louis et al. 2000).  This vector 
was eventually taken to the clinic with tragic results when the 18
th
 patient administered 
the vector, a man with partial ornithine transcarbamylase (OTC) deficiency, had an acute 
inflammatory system response that resulted in multi-organ failure and death (Raper, 
Chirmule et al. 2003).   
The safety concerns raised in this clinical trial prompted a period of introspection for the 
field of gene therapy. The field redirected its focus to a different vector system, one based 
on adenovirus-associated virus (AAV). This virus was originally discovered as a 
contaminant of adenovirus preps (Atchison, Casto et al. 1966).  A primary reason for the 
use of AAV vectors was the reduced innate immune activation by AAV compared to 
adenovirus (Zaiss, Liu et al. 2002).  With a small viral genome comprised of only two 
genes Rep, required for replication and Cap encoding for the protein capsid components 
it was able to be completed gutted with the gene’s removed for the therapeutic transgene 
(Zhou and Muzyczka 1998).  Also during this time a number of new AAV serotypes were 
discovered broadening the tissue types that could be targeted for transduction including 
AAV serotype 8 for liver and AAV serotype 9 for lung and the central nervous system 
(CNS) (Gao, Vandenberghe et al. 2005, Gao, Lu et al. 2006, Limberis and Wilson 2006, 
Hinderer, Bell et al. 2014, Hinderer, Bell et al. 2014).  Initial results reported that 
transduction of mice liver and muscle mediated tolerance of expression to non-self-
antigens (Carter and Samulski 2000).  However, despite the promise shown by initial 
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work, immune responses to AAV mediated gene therapy did arise albeit in a more 
subdued form than those that plagued adenovirus (Zaiss, Liu et al. 2002). 
AAV Vector Structure and Biology 
AAV, a parvovirus, has become the viral vector of choice for many in the field primarily 
due to its advantage over other vectors with its lower immunogenicity (Flotte and Carter 
1995) compared to that of adenovirus vectors and its lack of integration which has caused 
problems for retrovirus-based therapies (Hacein-Bey-Abina, Von Kalle et al. 2003).  
AAV is a simple virus generated from only two genes Rep and Cap which code for a 
helicase needed for genome replication (Im and Muzyczka 1990) and for the three 
subunits of the viral capsid, respectively.  The subunits that comprise the AAV capsid are 
VP1, VP2 and VP3 and give the particle its three dimensional conformation and contain 
regions of variability which can give different serotypes varying co-receptor affinities 
and tropism (Zincarelli, Soltys et al. 2008).  AAV vectors have had their genomes 
entirely replaced retaining only the inverted terminal repeats (ITRs) necessary for 
replication of the construct which form a double stranded hairpin at the ends of the linear 
vector genome (Bohenzky, Lefebvre et al. 1988); the genome therefore has both regions 
of double and single stranded DNA.  The AAV vector enters the cell through endocytosis 
and traffics through endosomes to the nucleus where it enters and un-coats (Ding, Zhang 
et al. 2005, Xiao and Samulski 2012).  The vector genome is then transcribed leading to 
expression of the transgene product where leader peptides will guide the therapeutic 
protein to its intended destination. 
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AAV Immunogenicity 
There are three main components of the AAV vector that have the potential to induce an 
immune response: a) capsid b) vector genome and c) the transgene product.  The capsid 
is, at best, a foreign protein the body has not yet encountered, however, since AAV is a 
naturally occurring virus many individuals have had previous exposure and may have 
antibodies to one or several serotypes (Calcedo, Vandenberghe et al. 2009).  Capsid 
specific T cells have also been found following vector administration in human clinical 
trials that lead to transduction attenuation (Manno, Pierce et al. 2006).  Additionally in 
our lab we have demonstrated that empty AAV capsid particles devoid of any genome are 
able to inherently induce an antibody response indicating that the capsid is not only a 
target of the adaptive immune response, but also inherently immune activating.  The 
vector genome has also been implicated as a major source of immunogenic material (Zhu, 
Huang et al. 2009, Martino, Suzuki et al. 2011, Rogers, Martino et al. 2011, Rogers, 
Martino et al. 2014).  Innate activation by vector genome is driven primarily through toll-
like receptor nine and myeloid differentiation primary response gene 88 (TLR9-MyD88) 
signaling.  Specifically plasmacytoid dendritic cells (pDC) express a high amount of 
TLR9 in endosomes which may be responsible for the initial inflammatory signaling by 
secretion of type one interferons.  Studies in TLR9 KO mice have implicated its 
importance in both innate and T cell activation by intramuscular administration of AAV 
vector (Zhu, Huang et al. 2009, Faust, Bell et al. 2013).  While MyD88 signaling seems 
important to anti-transgene antibody formation, the role of TLR9 is more complicated 
and it has been shown to have a limited effect on antibody generation despite downstream 
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signaling protein being vital (Rogers, Suzuki et al. 2015).  Finally, the gene of 
replacement and the gene product may elicit an immune response to the gene therapy.  
For the transgene product, as mentioned previously, the body may not recognize the 
protein as non-self and be capable of mounting an adaptive response to it (Figure 1).  
This is thought to be influenced by the underlying gene mutation, where a null mutation 
with no expression or non-null with some residual protein may alter the immune response 
outcome following AAV gene therapy (Cao, Hoffman et al. 2009, Rogers, Martino et al. 
2014).  It may also be possible for a non-null mutation to be immunogenic in its own 
right; the generation of a non-functional protein has the potential to cause toxicity or 
cellular stress which can lead to a pro-inflammatory state setting the stage for adaptive 
immune activation. (Carrell and Lomas 2002, Zhang, Wang et al. 2011). 
Unfolded Protein Response 
The unfolded protein response (UPR) is an important cell maintenance pathway which is 
responsible for cell survival in the event of cellular stress caused by an accumulation of 
improperly folded proteins usually found in the endoplasmic reticulum.  This pathway is 
well defined and mediated by three different branches controlled by a inositol-requiring 
protein-1 (IRE1), activating transcription factor-6 (ATTF6) and protein kinase RNA 
(PKR)-like ER kinase (PERK) (Ron and Walter 2007).  Activation of the UPR can either 
lead to resolution of the protein folding defect or death of the cell through activation of 
apoptotic pathways through the pro-apoptotic protein CHOP (Lai, Teodoro et al. 2007).  
Recent studies have linked the UPR to inflammation through several different 
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mechanisms.  Activation of NF-κB, a key transcriptional regulator in the onset of 
inflammation, has been proposed as one such mechanism.  Oxidative stress or calcium 
release induced by the UPR has been tentatively linked to NF-κB activation (Nakagawa 
and Yuan 2000).  Another direct link is through PERK-eIF2α attenuation of transcription.  
PERK senses accumulation of mis-folded protein accumulation when ER chaperone BiP 
disassociates with the PERK ER domains and binds to the unfolded proteins (Bertolotti, 
Zhang et al. 2000).  This results in PERK auto-phosphorylation which then 
phosphorylates eIF2α preventing the formation of the 80s ribosome and a non-specific 
protein synthesis inhibition (Kim, Son et al. 1998). In another study, UV irradiation was 
used to phosphorylate eIF2α and resulted in activation of NF-κB.  The authors concluded 
that the higher turnover of IκB an inhibitor NF-κB resulted in a depletion of IκB when 
translation was inhibited allowing NF-κB to migrate to the nucleus(Wu, Tan et al. 2004).  
Cross-talk between the UPR and inflammatory pathways also occurs, an example is the 
liver specific transcription regulator CREBH which can induce the acute phase response 
(ARP) and is itself induced by pro-inflammatory cytokines (Zhang, Shen et al. 2006).  
Activation occurs when ER stress induces CREBH to translocate to the Golgi apparatus 
and becomes cleaved by SP1 and SP2.  The functional transcription factor will mediate 
activation of ARP proteins (Zhang, Shen et al. 2006).  The mitochondrion is another 
cellular compartment that can induce cellular stress under its own mitochondria unfolded 
protein response (mtUPR).  This pathway is less well defined than the traditional UPR 
found in the endoplasmic reticulum but major signaling pathways have been discovered 
using a mutated form of mitochondria matrix protein OTC (Zhao, Wang et al. 2002, 
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Horibe and Hoogenraad 2007).  We also know that mitochondrial stress/oxidative stress 
can result in increases of inflammation in the liver a site of unique mitochondria activity 
(Satapati, Kucejova et al. 2015). 
Inflammation 
Successful activation of the adaptive immune response requires engagement of the innate 
immune system to create the necessary conditions for recruitment and priming of T and B 
cells known as inflammation.  This process begins when pattern recognition receptors, 
such as TLR9, start signaling upon exposure to their binding target.  These target 
molecules are either a molecule unique to a pathogen or, as is the case for TLR9, ones 
found in a compartment where endogenous molecules of that type are not normally 
located (Jounai, Kobiyama et al. 2012).  These patter recognition proteins can broadly be 
broken down into two classes those that recognize pathogen associated molecular 
patterns (PAMP) and ones that binding to markers of damage associated molecular 
patterns (DAMP).  The signaling cascade for TLRs, a class of PAMPs, leads to the 
freeing of transcription factor NF-kB from its inhibitor molecule, and subsequent 
migration to the nucleus where it can up-regulate the transcription of pro-inflammatory 
cytokines, such as type 1 interferons and IL-12 (Tsujimura, Tamura et al. 2004).  These 
cytokines recruit innate immune cells such as neutrophils and macrophages to which can 
both begin clearance of the disease vector through non-specific cell lysis, and contribute 
more cytokines to the inflammatory milieu.  Professional antigen presenting cells, such as 
dendritic cells, will also become licensed by inflammatory cytokines and be able to 
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present both the primary signal of the MHC-antigen complex to T cells, and stimulate co-
receptor molecules such as CD28 or inducible co-stimulator (ICOS) (Sallusto and 
Lanzavecchia 2002).  This secondary signaling event is important as without it T cells 
exposed to their specific MHC-antigen complex alone will undergo the process of 
anergy, becoming hypo-responsive and quiescent (Lin, Hensley et al. 2007).   
Antigen Presentation 
A major component of the adaptive immune system is its ability to recognize protein 
sequences conferring individual T cells antigen specificity.  The process of antigen 
presentation has multiple pathways that end with the loading of a linear poly-peptide 
antigen sequence onto major histocompatibility protein (MHC) which traffics to the cell 
surface where it can come into contact with a T cell receptor capable of binding to it 
(Hewitt 2003).  It is the amino acid sequence in combination with the MHC that confers 
specificity of bind to individual T cell receptors, each of which can be unique due to the 
process of V(D)J recombination.  MHC genes are polymorphic in both human and mouse 
populations, and this diversity can lead to difference in binding strength of it to antigen.  
The source of these poly-peptides has been a somewhat contentious debate in the field, 
divided amongst those who think that whole protein during the normal recycling of 
proteins is degraded by the proteasome and some of the products are further processed by 
catalytic enzymes before transport through the TAP channel into the ER for MHC 
loading (Colbert, Farfan-Arribas et al. 2013).  Other scientists have described a process 
where aborted translational event products comprise the majority of peptides trafficked 
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into the antigen presentation pathway, these products were first observed from early 
termination and have since been found in a variety of incomplete translation events 
(Yewdell, Anton et al. 1996, Dolan, Li et al. 2010, Dolan, Li et al. 2011).  These 
competing theories could have an important impact for gene therapy, as without antigen 
presentation an individual cannot be tolerant to a self-protein and if presentation is fueled 
primarily be retired full-length protein then people with a mutation that prevents all or 
partial translation would be likely to be intolerant to the mutated protein. 
Goals of this Dissertation 
In this dissertation I decided to investigate the factors involved in mediating the 
activation of an adaptive immune response to the transgene product following liver–
directed AAV gene therapy.  First, I created a model to explore the necessary stimuli 
needed to initiate a T cell response to a mitochondrial targeted protein OTC, and the 
resultant adverse events following adaptive immune activation.  I hypothesized that 
TLR9 activation would be necessary and sufficient to engage a T cell response and that 
this response would attenuate transgene expression by elimination of transduce cells.  In 
Chapter 2 I present my work using a transgenic mouse model to explore the activation 
and consequence of an anti-transgene CD8
+
 T cell response.  Also we studied the 
influence that genotype has on the ability to present antigen and induce anergy in CD8
+
 T 
cells.  As discussed in Chapter 3, to investigate the antigen presentation from premature 
termination codon (PTC) containing genes, I conducted a series of ex vivo antigen 
presentation assays to determine the method by which epitopes downstream of a PTC are 
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presented on MHC class I.  Subsequently, in in vivo experiments in mice I found that 
genes containing PTC were still able to induce anergy in CD8+ T cells to epitopes 
downstream of the mutation.  Finally, I sought to understand the factors that drive the 
activation of a humoral response against a secreted transgene product. In Chapter 4, it is 
discussed how we determined that TLR9 is necessary for the generation of an anti-
transgene antibody response.  Furthermore, I found that removal of transgene CpG motifs 
was insufficient to reduce anti-transgene responses and that CpG islands or other factors 
such as the tissue location of transgene expression play a vital role in humoral responses. 
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Figures 
 
Figure 1 Antigen presentation from transgene product 
A model of immune detection for an AAV vector and transgene product.  AAV vector, upon encountering 
its target cell will enter through endocytosis.  Once inside the cell AAV will escape the endosome or be 
digested as the compartment becomes increasingly acidified.  A portion of vector genomes will uncoat in 
the endosome and bind to TLR9 initiating a signaling cascade resulting in the translocation of transcription 
factor NF-kB to the nucleus.  This will result in the up-regulation of inflammatory genes.  Vectors that 
manage to escape the endosome can enter the nucleus through the nuclear pore.  Uncoating will occur 
inside the nucleus and the released genome can be made into double stranded DNA and transcribed.  The 
resulting transgene product will then as part of the natural turnover of proteins be ubiquitinated and traffic 
to the proteasome for degradation.  Some of the resultant peptide fragments will enter the endoplasmic 
reticulum (ER) through the TAP1/TAP2 channel.  Peptides in the ER will be further trimmed by proteases 
and then loaded onto the major histocompatibility complex (MHC).  The MHC-peptide complex will then 
traffic to the cell surface and present the antigen to its specific T cell. 
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Chapter 2 
TLR9 signaling mediates adaptive immunity against transgene products 
following systemic AAV gene therapy 
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Abstract 
Adaptive immune responses to the transgene product remain a concern for the field of 
gene therapy.  Driven by the immune stimulus of vector administration, transgene 
expression can elicit an adaptive immune response against the therapeutic protein, 
particularly for recessive diseases in which these antigens are not presented to 
lymphocytes during central tolerance induction.  Here, we show that TLR9 signaling is 
involved in driving the activation of CD8
+
 T cells against mitochondrial-targeted 
ornithine transcarbamylase (OTC) following systemic AAV vector administration.  Using 
a CD8
+
 T cell receptor transgenic mouse model system, we demonstrate that TLR9 
signaling extrinsic to T cells is sufficient to induce a robust cytotoxic T cell response 
against OTC, resulting in transgene expression loss.  Overall, our results suggest that 
inflammation mediated by TLR9 signaling is important for the development of adaptive 
immune responses to transgene products following AAV gene therapy. 
Introduction 
AAV vectors have shown potential in clinical trials to treat several recessive diseases by 
replacing the missing or defective gene (Simonelli, Maguire et al. 2010, Nathwani, Reiss 
et al. 2014, Jacobson, Cideciyan et al. 2015, Naldini 2015).  In many preclinical animal 
models, adaptive immune responses to the transgene product have been observed; this is 
particularly true when a “non-self” protein is expressed from the delivered gene, as the 
recipient may be more likely to develop an immune response to antigens that are not 
present during lymphocyte development (Fields, Kowalczyk et al. 2000, Ding, Hodges et 
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al. 2001, Limberis, Figueredo et al. 2007, Bradbury, Cochran et al. 2013, Ciesielska, 
Hadaczek et al. 2013).  However, the adaptive immune response is tightly controlled and 
exposure to a novel protein often results in tolerance rather than immunity, unless an 
inflammatory signal is present to initiate an adaptive immune response to the novel 
antigen (Lang, Georgiev et al. 2006).  One potential immunogenic stimulus associated 
with AAV-mediated gene therapy is the vector genome.  The immune system’s major 
sensing agent for this foreign material is TLR9, located in the endosomal compartment, 
which recognizes unmethylated CpG DNA and induces pro-inflammatory cytokine 
signaling that can result in an adaptive response (Hemmi, Takeuchi et al. 2000, Rogers, 
Martino et al. 2011). 
The ability of TLR9 to upregulate pro-inflammatory cytokines in response to AAV 
vectors has been observed both by ex vivo stimulation of plasmacytoid dendritic cells 
(pDCs) and by intramuscular (IM) AAV2 vector administration in mice (Zaiss, Liu et al. 
2002, Zhu, Huang et al. 2009).  Self-complementary AAV genomes containing double-
stranded DNA were implicated in more robust TLR9 activation resulting in a diminished 
induction of tolerance (Martino, Suzuki et al. 2011).  Additional work has been done to 
avoid TLR9-induced inflammatory signaling by CpG depletion or by increasing the CpG 
methylation state in DNA-based therapies (Reyes-Sandoval and Ertl 2004, Faust, Bell et 
al. 2013, Shapir, Miari et al. 2015).  However, there is evidence that TLR9 binds the 
phosphodiester backbone of DNA regardless of the nucleotide sequence, and that 
activation is merely enhanced by CpG motifs (Haas, Metzger et al. 2008).   
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I sought to investigate the influence of TLR9 on adaptive immune responses following 
AAV gene therapy using a systemic of administration for delivery to the liver.  I found 
that systemic inflammation mediated by a TLR9 agonist was able to break tolerance to 
the mitochondrially targeted ornithine transcarbamylase (OTC) protein and cause the 
destruction of transduced cells.  These findings suggest that, while TLR9 activation can 
be consequential in eliciting a transgene specific adaptive immune response, our ability to 
curb its influence may be limited. 
Materials and Methods 
Animals 
6-10 weeks of age OT-1 mice on a C57BL/6 background, C57BL/6, and B-cell -/- muMt
-
 
(stock number 002288) mice were acquired from The Jackson Laboratory (Bar Harbor, 
ME).  6-8 weeks of age TLR9 KO mice on a C57BL/6 background  mice were a kind gift 
from  Dr. Koretsky  (University of Pennsylvania, Philadelphia, PA); these mice  were 
created by Dr. Akira (Osaka University, Osaka, Japan) (Hemmi, Takeuchi et al. 2000).  
All mice were housed and bred under specific pathogen-free conditions in the 
Translational Research Laboratory Animal Facility at the University of Pennsylvania.  
Procedures were performed under IACUC approved protocols. 
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Vectors 
AAV2/8sc.TBG.hOTCco (self-complementary codon-optimized human ornithine 
transcarbamylase transgene under the control of a TBG promoter containing the 
G4SVPA poly A signal sequence) was produced by the University of Pennsylvania 
Vector Core.  To generate the sc.hOTCco-SIINFEKL transgene cassette, the 
immunodominant epitope of chicken ovalbumin (Ova257-264 SIINFEKL) was cloned into 
the sc.hOTCco transgene immediately following the C-terminal residue. 
Adoptive Transfer 
Mice were administered intravenously via the tail vein 1x10
11
 genome copies (GCs) of 
AAV8 expressing either sc.hOTCco-SIINFEKL or mutant variants in a total volume of 
100 µl PBS.  On day 14 post vector administration, CD8
+
 T cells were collected from 
OT-1 mouse spleens using CD8a
+
 T Cell Isolation Kit (Miltenyi Biotec, San Diego, CA).  
CD8
+
 T cell purity was >90%, as measured by flow cytometry.  Vector treated mice were 
then given 1x10
6
 CD8
+
 T cells in 100 µl PBS by tail vein injection.  Concurrent with 
adoptive cell transfer and for three days following, mice were given intraperitoneal (IP) a 
mixture of 20 µg TLR9 ODN 2395 and 20 ug ODN M363 (InvivoGen, San Diego, CA).  
For labeling T cells, CFSE (eBioscience, San Diego, CA) was diluted in DMSO to a 5 
mM stock solution.  T cells were resuspended to 5x10
7 
cells/ml.  1 µl of 0.5 mM CSFE 
was added to each ml of cell suspension and incubated at 37 ºC for 10 minutes.  Cells 
were then washed two times with DMEM and two times with PBS, before resuspension 
in PBS at a concentration of 1x10
7
 cells per ml.    Retro-orbital bleeds were performed 
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weekly throughout the study and samples were submitted to Antech Diagnostics (Irvine, 
CA) for analysis of transaminase and bilirubin levels. 
Epitope Mapping 
C57Bl/6 mice received IM 5x10
11
 GC of AAVrh32.33.CB7.hOTCco followed 12 weeks 
later by an intramuscular injection of 5x10
10
 particles (delivered as two 50 µl injections) 
of Ad5 vector expressing hOTCco.  On day 10 post Ad5 vector immunization, mice were 
sacrificed and splenocytes were harvested as described above (Section: Adoptive 
Transfer).  An interferon  (IFN-) ELISPOT assay (BD Biosciences, San Jose, CA) was 
performed according to the manufacturer’s instructions.  Cells were seeded at a 
concentration of 2x10
5
 or 2x10
4
 cells per well along with 2 g/ml of hOTC peptide pools 
or pool B containing an overlapping 15-mer peptide library (Mimotopes, Victoria, 
Australia) spanning the full length of the Ad5 hexon.  Splenocytes were incubated at 
37°C in 5% CO2 for 18 h.  Spot forming units (SFUs) were counted using the AID 
ELISPOT Reader System (Cell Technology, Columbia, MD).   
 
Liver Homogenization 
Livers previously harvested and frozen at -80c were ground in liquid nitrogen.  20 mg of 
ground liver and added 20 µL of 50 mM Tris buffer ph 7.5 (Sigma-Aldrich, St. Louis, 
MO)  per mg liver powder, then homogenize on ice for  5 seconds, 10 times.  We repeat 
homogenization routine once, then centrifuged at 13,200 rpm for 2 min and transfer 20 
 21 
 
µL supernatant into another new labeled tube with 180 µL 50 mM Tris buffer ph 7.5, 
homogenate can be kept on ice until use in activity assay. 
OTC Activity Assay 
We added 50 µl of diluted supernatant to 500 µl reaction buffer consisting of 5mM 
ornithine (Sigma-Aldrich, St. Louis, MO) in 50 mM Tris buffer pH 7.5.  To start the 
reaction we added 50 ul 4.8mM carbamyl phosphate (Sigma-Aldrich, St. Louis, MO) to 
reaction mixture and allow reaction to continue for 5 min at 25c.  The reaction was 
stopped by quenching with 500 µl of 5 mM C14 citrulline, 30% trichloroacetic acid 
(Sigma-Aldrich, St. Louis, MO).  Activity was determined by formation of citrulline as a 
ratio of C14 citrulline as measured by liquid chromatography–mass spectrometry. 
Biodistribution 
Liver samples were frozen on dry ice at the time of necropsy, and DNA was extracted 
using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA).  Detection and quantification 
of vector GCs in extracted DNA were performed by real-time PCR, as described 
previously (Bell, Moscioni et al. 2006).  Briefly, genomic DNA was isolated, and vector 
GCs were quantified using primers/probes designed against the sequence of the TBG 
promoter.  Quantification of GCs from liver was performed on one liver sample from 
each mouse. 
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RNA Analysis 
Liver samples were frozen in liquid nitrogen at the time of necropsy.  RNA was extracted 
using TRIZOL (Life Technologies, Carlsbad, CA), according to the manufacturer's 
protocol.  12 µg of RNA was then treated with DNase I (Roche, Basel, Switzerland), 
according to the manufacturer's protocol.  The RNeasy Mini Kit (Qiagen, Valencia, CA) 
was used to remove DNase prior to cDNA synthesis by reverse transcription using the 
Applied Biosystems High Capacity cDNA Reverse Transcriptase Kit (Life Technologies, 
Carlsbad, CA).  Real-time PCR was then performed on cDNA with primers binding to 
the hOTCco transgene with Power SYBR Master Mix for detection (Life Technologies, 
Carlsbad, CA). 
CD8 Stain on Frozen Sections 
Frozen liver sections were fixed in acetone at -20 ºC for 7 minutes, air dried, blocked in 
1% donkey serum (Jackson Immuno West Grove, PA) in PBS for 20 minutes, and 
incubated with 1:20 primary rat antibody against CD8 (clone 53-6.7, BD Biosciences) 
diluted in blocking buffer for 45 minutes.  After washing in PBS, sections were stained 
with secondary donkey antibodies labeled with FITC (Jackson Immunoresearch 
Laboratories, West Grove, PA) for 30 minutes, washed in PBS, and mounted in 
Vectashield immunofluorescence stain containing DAPI (Vector Laboratories, 
Burlingame, CA). 
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Ki67 Stain on Paraffin Sections 
Paraffin sections were deparaffinized through an ethanol and xylene series, boiled in a 
microwave for 6 minutes in 10 mM citrate buffer, pH 6.0 for antigen retrieval, and treated 
sequentially with 2% H2O2 (Sigma-Aldrich, St. Louis, MO) for 15 minutes, avidin/biotin 
blocking reagents (Vector Laboratories, Burlingame, CA) for 15 minutes, and blocking 
buffer (1% donkey serum (Jackson Immunoresearch, West Grove, PA) in PBS with 0.2% 
Triton) for 10 minutes.  Sections were then incubated for 1 hour with 1:500 primary 
rabbit serum against Ki67 (ab15580, Abcam, Cambridge, United Kingdom) and 45 
minutes with FITC-labeled secondary donkey antibody (Jackson Immunoresearch, West 
Grove, PA) diluted in blocking buffer. Sections were mounted using Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA) containing DAPI as a nuclear 
counterstain. 
Results 
In previous work, our group investigated the importance of inflammation on gene therapy 
in the liver using reporter gene, nuclear-targeted beta-galactosidase (nlacZ) (Somanathan, 
Breous et al. 2010, Breous, Somanathan et al. 2011).  Our results suggested that in the 
presence of a strong inflammatory signal, T cell targeting of a transgene product could 
result in the loss of transgene expression and destruction of transduced cells.  Thus, I 
probed the ability of TLR9 signaling to initiate a destructive cytotoxic T cell (CTL) 
response following gene therapy for human OTC (hOTC), a promising candidate for 
clinical applications.  First we attempted to determine if hOTC could be targeted by a 
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CTL response in C57BL/6 mice. However, even when expressing hOTC using an 
adenoviral vector, which is known to elicit strong immune responses following IM 
administration, a CTL response did not develop against hOTC (Figure 2 a). This may be 
due to the high level of OTC protein homology (92%) between human and mouse.  We 
attempted a more stringent regimen by priming the mice with 5x10
11
 GC of 
AAVrh32.33CB7.hOTCco, then administering 5x10
10
 particles of Ad5.hOTC with 
subsequent IP injections of TLR9 agonist to both the primed and an unprimed control 
group twelve weeks later (Figure 2 b).   While vector priming and TLR9 agonist 
administration led to a strong T cell activation against a hOTC epitope we determined 
that this was most likely the breaking of tolerance of antigen experienced T cells due to 
the transgene products’ similarity to mOTC.  In order to activate naive T cells against 
hOTC, we cloned a well-characterized antigenic peptide from chicken ovalbumin 
(Ova257-264 SIINFEKL) to the C-terminus of hOTC.  This model system allowed us to use 
OT-1 mice, which are transgenic for a SIINFEKL-specific T cell receptor (TCR) found 
on all T cells, to interrogate transgene-specific immune responses to systemic 
inflammation caused by TLR9 and its outcome on gene therapy.   
 The initial experiments with hOTCco-SIINFEKL were designed to investigate the 
behavior of the protein compared to the untagged version.  hOTCco-SIINFEKL was 
packaged in an AAV8 vector with a TBG promoter (AAV8.TBG. hOTCco-SIINFEKL). 
6-10 week old male SPF-Ash mice, a model of OTCD where activity is ~5% normal, 
were injected with either AAV8.TBG.hOTCco-SIINFEKL or the untagged 
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AAV8.TBG.hOTCco. Mice were evaluated for OTC enzyme activity at day 14 post 
administration (Figure 3 a) which showed minimal activity compare to control.  We also 
evaluated urine orotate a metabolic marker of OTCD and showed that correction was 
slower to occur in hOTCco-SIINFEKL treated mice (Figure 3 b).  We also investigated 
the ability of hOTCco-SIINFEKL to properly migrate to the mitochondria by transfecting 
the human liver cell line HuH7 on slide wells with OTC plasmids including one lacking 
the leader sequence required to guide the protein.  Transfected cells were probed with 
Mito Tracker CMXRos to visualize the mitochondria and following up take, they were 
fixed for OTC immunohistochemistry (Figure 4).  Staining revealed that hOTC-
SIINFEKL translocated to the mitochondria similar to wild type hOTC, whereas without 
the leader sequence hOTC is dispersed throughout the cytoplasm indicating a disruption 
of normal biogenesis which could impact antigen presentation.  Despite impaired OTC 
activity due to the addition of the tag, mitochondrial localization remained intact, and we 
will continue our investigation using hOTCco-SIINFEKL. 
 Male C57BL/6 mice 6-8 weeks old were treated with an intravenous (IV) 
injection of AAV8.TBG. hOTC-SIINFEKL.  Fourteen days after vector injection, 1x10
6
 
SIINFEKL specific T cells were adoptively transferred from OT-1 mice.  Concurrent 
with the adoptive transfer, we gave 40 µg of TLR9 agonist by IP injection (Figure 5 a).  
As anticipated, we only observed a CTL response (measured by transaminase levels) to 
the transgene product when both a population of transgene-specific OT-1 T cells and 
TLR9 inflammatory signals were present; transaminases aspartate transaminase (AST) 
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and alanine transaminase (ALT) were both elevated, indicating hepatocyte lysis (Figure 5 
b).  We also observed a ten-fold reduction in vector genome copy number and hOTCco 
mRNA in the livers of mice treated with both OT-1 T cells and TLR9 agonist, consistent 
with T cell mediated killing of transduced hepatocytes (Figure 5 c). We next tested 
whether a smaller T cell population (i.e., more similar in number to an endogenous, 
protein-specific naïve T cell population) could induce a comparable result (Moon, Chu et 
al. 2007, Jenkins and Moon 2012).  We found that as few as three thousand adoptively 
transferred cells could cause transaminase elevation (Figure 6 a).  We also observed a 
trend of decreased vector genome copies and reduced transgene mRNA ( Figure 6 b), 
although this was not statistically significant at lower doses. Finally we wanted to 
determine if exposure of T cells to antigen prior to an inflammatory event would inhibit 
transgene loss.  Inflammatory TLR9 agonist was either administered IP as before 
concurrent with CD8
+
 T cells or 21 days post adoptive transfer.  Transaminase elevations 
were muted in the late inflammation event group (Figure 7 a, b), as was transgene loss 
measured by mRNA or vector genomes though some did occur (Figure 7 c, d).  This 
mRNA loss may have been sufficient to reduce protein expression as in two mice the loss 
of protein was observed by western blot, however one of the mice did retain normal 
expression. 
 In order to directly evaluate T cell mediated killing of transduced cells in the 
liver, mice were treated with AAV8.TBG.hOTCco-SIINFEKL, OT-1 CD8
+
 T cells and 
40 µg TLR9 agonist as previously described, and sacrificed at 3, 7, and 14 days after 
 27 
 
adoptive transfer for histological evaluation of the liver.  Liver sections were stained for 
CD8a to mark CD8
+
 T cells, and infiltration was quantified by image analysis (Figure 8 
a, b).  Marked CD8
+
 T cell infiltration occurred at periportal and pericentral locations 
beginning on day 3; by day 7 the infiltrates with TLR9 agonist had penetrated deeper into 
the liver, whereas further penetration was not seen for T cells without the enhanced TLR9 
stimulation from administered agonist.  In both groups, infiltration was resolved by day 
14.  Our previous experiment suggested that hepatocyte death occurred following 
treatment with TLR9 agonist; however terminal deoxynucleotidyl transferase dUTP nick-
end labeling (TUNEL) staining and caspase-9 immunofluorescence did not show 
differences between control and experimental groups (data not shown).  As an indicator 
of cell death, we also examined the regrowth of hepatocytes that were predicted to have 
undergone lysis resulting in loss of AAV genomes (Figure 8 c).  Using Ki-67 staining to 
mark proliferation, we observed hepatocyte division to be spread out evenly across liver 
regions in the experimental groups, mirroring the degree of CD8+ T cell infiltration.  We 
determined the percent of hepatocytes that were Ki-67 positive by image analysis (Figure 
8 d), and found hepatocyte division to be much higher than the normal expected rate of 
turnover, indicating increased cell death above background (Miyaoka, Ebato et al. 2012, 
Miyaoka and Miyajima 2013).  By determining genome copies at each time point (Figure 
8 e), we observed that most loss occurred between three and seven days post adoptive 
transfer, correlating with the histology results (Figure 8 a, c); together, these data indicate 
that the majority of T cell infiltration and hepatocyte death occurs during this time span 7 
to 14 days. 
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 Next, we examined whether the infiltrating cells were indeed transgene-specific 
CTLs.  We labeled CD8
+
 T cells with CFSE fluorescent cell staining dye before delivery 
into C57BL/6 mice previously administered with AAV8.TBG.hOTCco-SIINFEKL.  
Seven days after adoptive transfer and TLR9 stimulation, we isolated lymphocytes from 
the liver or spleen, and stained them with anti-CD8a and SIINFEKL tetramer (Figure 9 b, 
c).  The majority of liver-isolated lymphocytes were tetramer positive, regardless of 
whether mice received TLR9 agonist (Figure 9 c).  In contrast, the majority of spleen 
isolated T cells were tetramer positive only if the mice received TLR9 agonist. In 
addition, CFSE staining of tetramer positive splenocytes remained high in mice that did 
not receive TLR9 agonist (Figure 9 d) suggesting that transgene-specific activation of 
CD8
+
 T cells in the presence of TLR9 stimulation increased proliferation.  We then 
sought to determine if intrinsic TLR9 signaling in transferred T cells alone would trigger 
an immune response, or if extrinsic signaling was required for the effect.  We 
administered 6-8 week old male C57BL/6 mice or TRL9 -/- mice with 
AAV8.TBG.hOTCco-SIINFEKL.  Fourteen days later, we adoptively transferred 1x10
6
 
OT-1 CD8
+
 T cells into recipient mice that were also given 40 µg TLR9 agonist (Figure 
10 a).  AST and ALT elevation only occurred in the C57BL/6 group; despite TLR9 
signaling being intact in transferred OT-1 T cells, this was insufficient to activate a robust 
CTL response (Figure 10 b,c).  These results indicate that the TLR9 signaling required 
for initiating T cell responses must be extrinsic to the T cells themselves, perhaps 
occurring in transduced hepatocytes or antigen-presenting cells. 
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Discussion 
Adaptive immune responses to a transgene product are complex from activation 
of antigen presenting cells to the balance of a productive to destructive immune response.  
Thus, when determining the best method for delivering a successful treatment, there are 
many factors to consider, such as the route of administration and vector genome 
composition.  These components may have a dramatic effect on the likelihood that a 
given therapy will induce an inflammatory environment, elicit an adaptive anti-transgene 
response, and lead to an ineffective treatment (Cao, Hoffman et al. 2009, Martino, Suzuki 
et al. 2011, Rogers, Martino et al. 2014).  Here, we show that loss of TLR9 signaling 
dramatically attenuates the CTL responses against the transgene following IV 
administration of an AAV vector.  
Relevant to our interest in liver-directed gene therapy for metabolic disorders, we 
examined transgene-specific T cell response to a mitochondrially targeted protein, OTC.  
Given the previous evidence of minimal immune responses following liver-directed gene 
transfer with AAV vectors, we anticipated that hepatic OTC expression would not elicit a 
robust immune response (Lang, Georgiev et al. 2006).  The high homology between 
mouse and human protein complicated matters.  In an ideal model, there would be no 
prior exposure to the transgene product; however, the OTC -/- model is neonatal lethal, 
and the SPF-Ash OTCD mouse line still expresses residual (around 5% of normal) 
activity(Wang, Wang et al.).  Therefore, we added the immune-dominant epitope Ova257-
264 to the C-terminus of hOTC to increase its immunogenicity.  While addition of the 
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SIINFEKL epitope reduced OTC activity of the construct, mitochondrial localization was 
retained and so therefore we would expect turnover and antigen processing to be similar.  
Using the OVA epitope allowed us to measure and manipulate the transgene-specific T 
cell population for more sensitive readouts of immune activation.  Using OT-1 transgenic 
T cells, we demonstrated that a robust response against the transgene product could be 
mediated by the activation of TLR9.  This immune response was characterized by large 
elevations in transaminases and loss of transgene expression, as measured by hOTC-
SIINFEKL mRNA and genome copy levels.  We also observed that antigen-specific T 
cell populations of as low as 3,000 cells could induce transaminase elevation and 
modestly decrease genome copy number.  In addition we showed that inflammation after 
transgene expression and presumed exposure to CD8
+
 T cells resulted in an attenuated 
clearance of the transgene and product, indicating that the most at risk timeframe for a 
robust immune response is during first contact of antigen to the T cells which will occur 
when expression begins a few days following vector administration.  Further, we 
observed increased T cell infiltration of predominantly transgene-specific T cells, which 
corresponded to an increase in hepatocytes entering the cell cycle and subsequent loss of 
genome copies.  Together, these data suggest that as hepatocytes are destroyed, dividing 
cells replicate to replace them.  An alternative hypothesis could be that the cell division is 
responsible for the loss of the genome copies that are not retained when the nuclear 
envelope is dissolved and reformed; this possibility is supported by the lack of an 
increase in TUNEL or caspase 9 staining.  As systemic administration of TLR9 agonist 
induced T cell activation against the transgene product, we were curious as to whether 
 31 
 
TLR9 signaling intrinsic to T cells alone would be sufficient to activate them.  We used 
TLR9 KO mice as recipients of the OT-1 T cell transfer.  Our results showed that TLR9 
signaling extrinsic to T cells was required for activation, such as both B cells and pDCs 
that respond strongly to TLR9 stimulation (Montoya, Jie et al. 2006, Jiang, Lederman et 
al. 2007).  Therefore, future studies may help to further our knowledge and ability to 
design less immunogenic AAV vectors. 
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Figure 2 hOTC Immunodominant Epitope Mapping in C57BL/6 mice.   
(A) C57BL/6 mice were given IM 5x10
10
 p Ad5 hOTC.  Mice (n=3) were sacrificed 28 days later, and IFN-
gamma ELISPOT was performed on isolated T cells.  (B)  One cohort of C57Bl/6 mice was injected IM 
with 5x10
11
 AAVrh32.33 CB7.hOTCco twelve weeks later mice were injected IM with 5x10
10
 of 
Ad5.hOTC vector and TLR9 agonist 40 µg IP concurrent with ad administration and for the three following 
days N=4.  10 days after vector administration mice were sacrificed for IFN ɣ ELISPOT.   
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Figure 3 Evaluation of OTC-SIINFEKL Activity in vivo. 
Male SPF-Ash mice (n=3) ages 6-10 weeks were injected IV with AAV8.TBG.hOTCco or 
AAV8.TBG.hOTCco-SIINFEKL 1x10
11
 GC.  (A) Mice urine was collected and urine orotate was 
measured.  (B)  OTC enzyme activity was assayed from liver collected at day 14 necropsy. 
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Figure 4 hOTC-SIINFEKL Mitochondria Localization 
 Huh7 cells were transfected in slide well plates with plasids that contained hOTC transgenes.  48 hours 
after transfection MitoTracker is added to media to visualize mitochondria (red) cells are fixed thirty 
minutes later for OTC immunohistochemistry (green) and nuclear DAPI (blue). 
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Figure 5  Systemic Inflammation Breaks Tolerance to a Transgene Product.  
(A)  Schematic of experimental design detailing IV administration of AAV8.TBGhOTCco-SIINFEKL and 
subsequently OT-1 CD8+T cell transfer at 14 days after vector delivery, concurrent with administration of 
40 µg TLR9 agonist for three days following adoptive transfer, n=3.  (B) Serum AST and (C) Serum ALT 
levels were monitored every seven days following vector delivery.  (D) Genome copies and  (E)  transgene 
mRNA from liver were determined by qPCR following termination of the study.  These experiments were 
independently performed three times. Statistical analysis was performed by one-way ANOVA with 
Bonferroni test comparing to vector only control *P<0.05, **P<0.001, ***P<0.0001. 
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Figure 6 Effect of T cell population on Immune Response.   
6-8 week old male C57Bl/6 mice (n=3) were given IV XX GC of AAV8.TBGhOTCco-SIINFEKL. 
Twenty-eight days after vector delivery, OT-1 CD8+T cells were transferred to recipient mice concurrent 
with 40 µg TLR9 agonist administration for three days following adoptive transfer.  (A) Serum AST (B) 
ALT and (C) bilirubin levels were monitored every seven days following vector delivery.  (D) Genome 
copies and (E) transgene mRNA from liver were determined by qPCR following termination of the study.  
Analysis was performed by one-way ANOVA with Bonferroni test comparing to no transfer control 
*P<0.05, **P<0.001, ***P<0.0001. 
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 Figure 7 Inflammation after T cell to Antigen Exposure  
6-8 week old male C57Bl/6 mice (n=3) were injected IV with AAV8 hOTCco-SIINFEKL.  Fourteen days 
after vector delivery, OT-1 CD8
+
T cells were transferred to recipient mice concurrent with 40 µg TLR9 
agonist administration that continued for three days following adoptive transfer or with the TLR 9 agonist 
given 21 post adoptive transfer, control mice were not given agonist. (a ,b) Serum AST and ALT levels 
were monitored every seven days following vector delivery.  (c, d) Genome copies and transgene mRNA 
from liver were determined by qPCR following termination of the study.  (e) Western blot probed for OTC, 
the OTC-SIIFEKL band migrates above the endogenous OTC.  
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Figure 8  T cell Infiltration and Hepatocyte Proliferation.    
Vector was administered to 6-8 week old male mice (n=4) IV and 14 days later OT-1 CD8
+
T cell were 
transferred, concurrent with administration of 40 ug TLR9 agonist for three days following adoptive 
transfer.  Mice were sacrificed on days three, seven, and 14 following CD
+
 T cell transfer.  (a, b) Liver 
sections were stained for CD8, and percent area covered by infiltrating T cells was determined using Image 
J.  (c, d) Liver sections were stained for Ki-67 proliferation marker, and percent positive hepatocytes were 
calculated.  (e) AAV vector genome copies were determined by qPCR following termination of each 
cohort.  For image analysis experiments, five images per mouse were analyzed.  Analysis was performed 
by one-way ANOVA with Bonferroni test comparing columns to their day appropriate control *P<0.05, 
**P<0.001, ***P<0.0001.  NS, not significant. 
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Figure 9 Transgene-Specific T cell Infiltration. 
6-8 week old male C57Bl/6 mice (n=4) were given AAV8 hOTC-SIINFEKL; 14 days later TLR9 agonist 
and CFSE-labeled OT-1 CD8
+
 T cells were administered.  Mice were sacrificed seven days following CD8
+
 
T cell transfer, and lymphocytes were isolated from liver and spleen.  (a ,c) Lymphocytes isolated from 
spleen or liver by forward and side scatter were stained for CD8.  (b) Spleen- and (d) liver-isolated CD8
+
 T 
cells were stained with SIINFEKL tetramer.  (f, e) Tetramer positive splenocytes were analyzed for CFSE 
retention. 
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Figure 10 Extrinsic TLR9 Signaling is Required for a Destructive CTL Response 
(a) C57BL/6 or TLR9 KO male mice (n=5) ages 6-8 weeks were administered IV AAV8 expressing 
hOTCco-SIINFEKL. Fourteen days after vector delivery, OT-1 CD8+T cells were transferred to recipient 
mice concurrent with 40 µg TLR9 agonist administration that continued for three days following adoptive 
transfer.  (b-c) Serum (b) AST and (c) ALT levels were monitored every seven days following vector 
delivery.  Genome copies and transgene mRNA expression was determined following termination of the 
study by the study. 
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Chapter 3:  
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Abstract 
Cytotoxic T cell (CTL) responses to the transgene product remain an active area of 
concern for the gene therapy field.  The patient’s underlying genetic mutation may 
influence the qualitative nature of these potentially destructive T cell responses.  
Individuals with a mutation that introduces a premature termination codon (PTC) 
preventing synthesis of full-length peptide have been considered more likely to mount a 
transgene-specific T cell response due to a lack of endogenous antigen presentation and, 
therefore, no immune tolerance to C-terminal epitopes.  Here, we demonstrate that a 
human ornithine transcarbamylase (OTC) gene containing various PTC-inducing 
nonsense mutations is able to generate and present epitopes downstream of the 
termination codon.  Generation of these epitopes occurs primarily from alternative 
translation start sites downstream of the stop codon.  Furthermore, we show that 
expression of these genes from AAV vectors in C57Bl/6 mice is able to induce peripheral 
tolerance to epitopes downstream of the PTC.  These results suggest that, despite the lack 
of full-length endogenous protein, patients with PTC-inducing nonsense mutations may 
still present T cell epitopes downstream to the premature termination that may render the 
subject tolerant to wild-type transgene products, and therefore less likely to generate a 
transgene-specific immune response resulting in an overall improved therapeutic 
outcome.  
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Introduction 
OTC deficiency is a rare X-linked metabolic disorder that is considered a therapeutic 
target for gene therapy (Hudak, Jones et al. 1985, Nguyen and Ferry 2004).  Most OTC 
gene mutations are “private”, meaning that they are unique to a particular individual or 
family, and thereby result in a patient population with a diverse array of mutations 
(Yamaguchi, Brailey et al. 2006).  While some groups have begun to investigate the 
influence of genotype on immune responses to the transgene product in other genetic 
disorders (Cao, Hoffman et al. 2009, Nayak, Doerfler et al. 2014, Rogers, Martino et al. 
2014), the impact of these diverse mutations on the outcome of gene therapy for OTC 
remains unknown.  Because OTC localizes to the mitochondria, the development of 
transgene-specific T cells may be more likely and problematic than an antibody response 
(Limberis, Figueredo et al. 2007, Mendell, Campbell et al. 2010, Flotte, Trapnell et al. 
2011).  Whereas a healthy individual could deplete transgene-specific T cells via 
mechanisms of central and peripheral tolerance (Mendell, Campbell et al. 2010, Flotte, 
Trapnell et al. 2011), the OTC-deficient patient with mutations that eliminate expression 
of the protein (or parts of the protein) may be unable to induce tolerance to the wild-type 
gene, rendering them susceptible to CTL responses upon transgene delivery.  Indeed, 
preclinical evidence in other disease models suggests that certain mutations may limit 
tolerance induction and predispose patients receiving gene therapy to a T cell mediated 
transgene response (4-6). 
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Presentation of self-antigens on the major histocompatibility complex (MHC) is 
necessary to develop tolerance against endogenous epitopes by deleting or anergizing 
self-reactive T cells (Kappler, Roehm et al. 1987, Schwartz 2003).  Tolerance to self-
antigens is mediated by several mechanisms, including the deletion of auto-reactive T 
cells in the thymus and active suppression or induction of anergy in the periphery, all of 
which require the presentation of self-antigens in primary lymphoid organs (Fields, 
Gajewski et al. 1996, Pobezinsky, Angelov et al. 2012).  As such, the impact of genetic 
mutations on antigen presentation has the potential to influence tolerance induction. 
Genetic defects that allow the expression of a full-length non-functional protein are 
thought to result in tolerance to epitopes derived from that gene; in contrast, deletions, 
frameshifts, and nonsense mutations that prevent full-length protein expression (i.e., null 
mutations) may impair the ability to develop tolerance and could predispose individuals 
who receive gene therapy to a T cell-mediated transgene response (Fields, Arruda et al. 
2001, Herzog, Mount et al. 2001, Herzog, Fields et al. 2002).  Nonsense mutations can 
also result in truncated non-functional proteins, where tolerance induction may be limited 
to epitopes upstream of the PTC.  In addition, mutations leading to a PTC increase the 
rate of mRNA degradation due to nonsense-mediated decay (NMD) mechanisms, which 
may further limit potential antigen presentation and tolerance induction (Lykke-Andersen 
and Jensen 2015). 
An extensive body of work suggests that the majority of antigens presented on the MHC 
are not derived from the degradation of mature full-length protein but from defective 
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ribosomal initiation products (Yewdell, Anton et al. 1996, Dolan, Li et al. 2010, Dolan, 
Li et al. 2011, Croft, Smith et al. 2013).  The work of Shastri and colleagues has 
demonstrated translation of unconventional start sites leads to cryptic peptides capable of 
MHC I mediated induction of T cells (Starck and Shastri 2011, Starck, Jiang et al. 2012, 
Starck and Shastri 2016, Vilborg and Steitz 2016). Furthermore, evidence suggests that 
epitopes can also be generated from the N-terminal region upstream of a nonsense 
mutation during the first or pioneering run of translation (Apcher, Daskalogianni et al. 
2011).  Here, we investigate the ability of mice to present antigens and tolerize CD8
+
 T 
cells to epitopes downstream of a nonsense mutation. Our findings reveal a previously 
unknown mechanism of epitope presentation downstream of a PTC.  This finding could 
result in the re-evaluation of how an individual’s genotype could influence the outcome 
of gene therapy. 
Materials and Methods 
Animals 
OT-1 mice on a C57Bl/6 background were acquired from The Jackson Laboratory (Bar 
Harbor, ME) and bred at our facility (Animal Facility of Translational Research 
Laboratories [TRL], University of Pennsylvania, Philadelphia, PA).  All mice were 
housed under specific pathogen-free conditions in the TRL Animal Facility at the 
University of Pennsylvania.  All experimental procedures, including the use of mice, 
were performed in accordance with protocols approved by the Institutional Animal Care 
and Use Committee of the University of Pennsylvania. 
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Vectors 
AAV8 vectors expressing a single-stranded, nuclear-targeted form of β-galactosidase 
(AAV8.ss.nLacZ), or a self-complementary human codon-optimized ornithine 
transcarbamylase (AAV8.sc.hOTCco) were designed under the control of TBG promoter, 
with a G4SVPA poly(A) signal sequence.  To create the sc.hOTCco-SIINFEKL 
transgene, the immunodominant epitope of chicken ovalbumin [Ova257-264 (SIINFEKL)] 
was cloned onto the C-terminus directly following the last hOTCco amino acid.  Site-
directed mutagenesis was used to create the sc.hOTCco-SIINFEKL stop codon mutants: 
C109X, R141W, and Q154X.  An AAV8.sc.hOTCco-SIINFEKL vector was designed 
containing the TBG enhancer/promoter and an SV40 poly(A) tail. AAV vectors were 
produced as previously described using an iodixanol step gradient (Lock, Alvira et al. 
2010).  E1/E3-deleted, replication-deficient, serotype 5 adenoviral vectors (Ad5) 
expressing hOTCco-SIINFEKL, hOTCco-C109X-SIINFEKL, or cytoplasmic-targeted 
chicken ovalbumin were produced as previously described (Gao, Yang et al. 1996).  All 
vectors were produced by the Penn Vector Core at the University of Pennsylvania. 
 
Ex-vivo stimulation assay 
MC57G cells, a fibrosarcoma cell line expressing both H-2Kb and H-2Kd, were seeded 
on 6-well plates to achieve 70% confluence after 18 h.  Transfection using Lipofectamine 
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(Life Technologies, Grand Island, NY) was performed according to the manufacturer’s 
instructions.  Cells were transfected with a plasmid containing either hOTCco-SIINFEKL 
or the hOTCco-SIINFEKL stop codon mutants that were developed using site-directed 
mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s 
instructions.  After 24 h post-transfection, 6-well plates were washed once with PBS, 
cells were mechanically scraped off the plate and into suspension, and washed once more 
before being resuspended at 2x10
6
 cells/ml, seeding 100 l/well on an enzyme-linked 
immunospot (IFN-ɣ ELISPOT) plate (BD Biosciences, San Jose, CA).  OT-1 splenocytes 
were harvested from OT-1 mice as previously described (Limberis, Figueredo et al. 2007) 
and then seeded 1:1 or 1:10 with the MC57G cells.  This combination was then incubated 
at 37°C in 5% CO2 for 18 h.  The ELISPOT plate was developed according to the 
manufacturer’s protocol, and spots were counted using the AID ELISPOT Reader System 
(Cell Technology, Columbia, MD).  
Tolerance induction 
Mice received 1x10
11
 genome copies of AAV8 expressing either sc.hOTCco-SIINFEKL, 
sc.hOTCco-SIINFEKL stop codon mutants, or an ss.nLacZ control, delivered IV in 100 
l of PBS.  On day 14 post vector administration, 1x1010 GC of Ad5.TBG.hOTCco-
SIINFEKL or 3x10
9
 particles of Ad5.TBG.OVA were injected IV.  Mice were sacrificed 
and splenocytes were harvested on day 27 after vector administration as previously 
described (Limberis, Figueredo et al. 2007).  An interferon  (IFN-) ELISPOT assay 
(BD Biosciences, San Jose, CA) was performed according to the manufacturer’s 
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instructions.  Cells were seeded at a concentration of 2x10
5
 or 2x10
4
 cells per well along 
with 2 g/ml SIINFEKL peptide or pool B containing an overlapping 15-mer peptide 
library (Mimotopes, Victoria, Australia) spanning the full length of the Ad5 hexon.  
Splenocytes were incubated at 37°C in 5% CO2 for 18 h.  Spot forming units (SFUs) 
were counted using the AID ELISPOT Reader System (Cell Technology, Columbia, 
MD).  Tetramer staining was performed according to the manufacturer’s instructions 
(MBL International, Woburn, MA).  Splenocytes were resuspended to a concentration of 
5x10
6 
cells/ml.  200 l of the cell suspension was stained with either 2 l iTAg 
Tetramer/PE-H-2 Kb OVA (MBL International, Woburn, MA) and 3 l anti-mouse 
CD8-APC (Clone 53-6.7; eBiosciences, San Diego, CA), or a cocktail containing 2 l 
iTAg Tetramer/PE-H-2 Kb OVA, 2 l CD62L-FITC (Clone MEL-14), 3 l PD-1-APC 
(Clone RMPI-30), and 1 l CD44-PE-Cyanine7 (Clone IM7; eBiosciences, San Diego, 
CA), then incubated for 30 min in the dark at room temperature.  Cells were washed with 
PBS, resuspended in 500 l PBS with 1% FBS, and run on an FC 500 series flow 
cytometer (Beckman Coulter, Brea, CA).  Analysis was performed using FlowJo software 
(Becton Dickinson, Franklin Lakes, NJ) 
 Adenoviral vector immunization 
Mice received 5x10
10
 p of Ad5 expressing either hOTCco-SIINFEKL, nonsense mutant 
variant C109X (hOTCco-C109X-SIINFEKL), or an nLacZ control delivered IV in 100 l 
PBS.  On Day 10 post vector immunization, mice were sacrificed and splenocytes were 
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harvested as described above.  An IFN- ELISPOT assay was performed on harvested 
splenocytes as described in the previous section. 
Peptide Isolation 
Cloning was used to swap out SIINFEKL with a StrepII tag with a SerAla linker (SA-
WSHPQFEK) on hOTCco-C109X.  Nine, 15 cm plates of HEK 293T cells were 
transfected per condition using 3 g polyethylenimine per 1 g DNA with either 
hOTCco-C109X-StrepII or eGFP; cells were grown for 24 h.  Proteasome inhibitor 
MG132 (APExBIO, Houston, TX) was added to the cells to reach a concentration of 1 
M.  Two h after proteasome addition, cells were harvested using a gravity-flow Strep-
Tactin sepharose column (IBA, Goettingen, Germany).  Media was removed and cells 
were washed twice with PBS containing 1 M proteasome inhibitor MG132 at 1500 rpm; 
all spins are performed at 4C.  Cells were resuspended in 2 ml of Strep-Tactin wash 
buffer with 25 M MG132 and 1X complete protease inhibitor (Sigma Aldrich, St Louis, 
MO).  Cells were lysed by five freeze-thaw cycles in liquid nitrogen, followed by a 37C 
water bath.  DNA was sheared by passing lysate through 18G needles five times over ice.  
Lysate was spun down at 4000 rpm for 15 min.  Supernatant was collected and spun 
down at 14,000 rpm for 5 min.  StrepII-tagged peptides were collected using 1 ml gravity 
flow Strep-Tactin sepharose columns (IBA, Goettingen, Germany), as per manufacturer’s 
instructions.  Fractions were analyzed using Novex NuPAGE SDS-PAGE (Invitrogen, 
Carlsbad, CA), per manufacturer’s instructions and stained with Sypro Ruby Protein stain 
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(Thermo Fisher Scientific, Waltham, MA).  Sample fractions were submitted for mass 
spectrometry analysis (Bioproximity, Chantilly, VA). 
Protein Denaturation, Digestion, and Desalting 
Samples were sent to Bioproximity (Chantilly, VA) for digestion using the filter-assisted 
sample preparation method (Wisniewski, Zougman et al. 2009).  Briefly, the samples 
were suspended in 5% sodium deoxycholate SDC, 50 mM Tris-HCl, pH 7.6, 3 mM DTT; 
they were sonicated briefly and incubated in a ThermoMixer (Eppendorf, Hauppauge, 
NY) at 60C with 1000 rpm for 20 min.  Samples were centrifuged, and the supernatant 
was transferred to a 30 kD molecular weight cut-off device (Millipore, Billerica, MA) 
and centrifuged at 13,000 g for 30 min.  The remaining sample was buffer exchanged 
with 1% SDC in 100 mM Tris-HCl, pH 7.6 and alkylated with 15 mM iodoacetamide.  
Samples were digested using trypsin at an enzyme to substrate ratio of 1:100, overnight at 
37C in a ThermoMixer at 1000 rpm.  Digested peptides were collected by 
centrifugation.  A portion of the digested peptides (about 20 µg), were desalted using 
reversed-phase stop-and-go extraction tips (Rappsilber, Mann et al. 2007).  Peptides were 
eluted with 80% acetonitrile, 5% ammonium hydroxide and lyophilized for 
approximately 1 h in a Savant SpeedVac (Thermo Fisher Scientific, Waltham, MA) to 
remove volatile components. 
Liquid Chromatography-Tandem Mass Spectrometry 
Each digestion mixture was analyzed by ultra-high pressure liquid chromatography (LC) 
mass spectrometry (MS)/mass spectrometry by Bioproximity (Chantilly, VA) . LC was 
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performed on an EASY-nLC 1000 system (Thermo Fisher Scientific, Waltham, MA).  
Mobile phase A was 97.5% Milli-Q water (Millipore, Billerica, MA), 2% acetonitrile, 
and 0.5% acetic acid; mobile phase B was 99.5% acetonitrile and 0.5% acetic acid.  The 
35 min LC gradient ran from 0% B to 25% B over 20 min, and then to 80% B for 3 min.  
Samples were loaded directly onto the 15 cm x 50 µm I.D. EASY-Spray column (Thermo 
Fisher Scientific, Waltham, MA), packed with 2 µm PepMap C18 media (Thermo Fisher 
Scientific, Waltham, MA).  The LC system was interfaced to a Q Exactive Hybrid 
Quadrupole Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA) via 
nano-electrospray ionization using an EASY-Spray source with an integrated column 
heater (Thermo Fisher Scientific, Waltham, WA).  The column was heated to 50C, and 
an electrospray voltage of 2.2 kV was applied.  The mass spectrometer was programmed 
to acquire, by data-dependent acquisition, tandem mass spectra from the top 20 ions in 
the full scan from 400-1200 m/z.  Dynamic exclusion was set to 15 s, singly-charged ions 
were excluded, isolation width was set to 1.6 Da, full MS resolution was set to 70,000 
and MS/MS resolution was set to 17,500.  Normalized collision energy was set to 25, 
automatic gain control to 2e5, max fill MS to 20 ms, max fill MS/MS to 60 ms, and the 
underfill ratio to 0.1%. 
Statistical analysis 
All statistics were performed using Prism 5 (GraphPad, La Jolla, CA).  One-way 
ANOVA analysis with Dunnett's Test was performed on each experimental replicate in 
the study.  Data are shown from a representative experiment for each study.  For all 
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figures, significance is depicted as *p<0.05, **p<0.001, ***p<0.0001.  The number of 
animals per group, biological replicates and experimental replicates are defined in the 
figure legends. 
  
 54 
 
Results 
Antigen presentation of epitopes downstream of a nonsense mutation 
  We set out to investigate the impact that mutations in hOTC cDNA could have on 
MHC class I antigen presentation.  We designed a panel of hOTC constructs (Figure 11 
a) into which we inserted an array of mutations previously reported in patients (Table 1) 
(Grompe, Muzny et al. 1989, Carstens, Fenton et al. 1991, Oppliger Leibundgut, 
Wermuth et al. 1996, Oppliger Leibundgut, Wermuth et al. 1996, Matsuda and Tanase 
1997, Calvas, Segues et al. 1998).  The codons selected for translation of the hOTC 
protein in these cDNA constructs were optimized for efficient translation using standard 
algorithms (Wang, Morizono et al.).  Redundancy in the genetic code allows for several 
codons to translate into same amino acid.  We used the more preferred human codon 
when multiple codons existed for a single amino acid, by selectively replacing the rare 
codons, this should result in an increase in the expression without changing the amino 
acid sequence (Mauro and Chappell 2014). An immunodominant H2-K
b
 epitope from 
chicken ovalbumin (amino acid residues 257-264; SIINFEKL) was inserted at the C-
terminus of each construct (Figure 11 a).  To facilitate the presentation of the SIINFEKL 
epitope on MHC class I molecules, we transfected mouse-derived MC57G fibroblast cells 
with each of the plasmid constructs.  Then we performed IFN- ELISPOT assays to 
determine if the transfected cells were able to stimulate splenocytes derived from OT-1 
mice, which express a transgenic T cell receptor that recognizes SIINFEKL presented in 
MHC class I molecules (Figure 11).  Our results indicate that all missense mutations 
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(R26Q, L88N, P225L, T264A, and H302Y) showed comparable antigen presentation and 
T cell activation to wild-type hOTCco-SIINFEKL which was expected since this 
category of mutation should not interfere with translation and presentation of the C 
terminal SIINFEKL epitope. Interestingly, the three nonsense mutants (C109X, R141X, 
and E154X) also generated robust T cell activation indicative of antigen presentation 
(Figure 11 b). This finding indicates that, despite the presence of a PTC, the downstream 
SIINFEKL epitope was still translated and presented. 
To determine whether codon optimization impacted the ability to present C-
terminal epitopes in this system, we compared codon-optimized with non-codon-
optimized human sequences (Figure 17 a).  T cell activation was still observed in wild-
type codon-optimized sequences as well as those containing nonsense and frameshift 
mutations upstream of the SIINFEKL epitope (Figure 17 a).  In non-Lipofectamine 
transfection controls, T cell activation was ablated, demonstrating that transfection of our 
plasmid constructs, and not residual protein contamination within the plasmid preps, was 
responsible for generating the observed anti-SIINFEKL immune response (Figure 17 b). 
Translation initiation via alternative start sites generates epitopes downstream of a 
nonsense mutation 
We considered two general mechanisms by which epitopes downstream of a 
nonsense mutation could be presented on MHC class I molecules: a) read through of the 
stop mutation and b) initiation of translation downstream of the stop mutation. To 
investigate these two mechanisms, we designed an expanded panel of hOTCco-
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SIINFEKL stop codon mutants including the original C109X, R141X, and E154X 
nonsense mutants as well as three new constructs containing: three consecutive nonsense  
mutations (CPL-109-111X), a +1 frameshift mutation (P110+1), and a nonsense mutation 
near the C-terminus (K353X) (Figure 12 a).  Interestingly, the triple-stop CPL-109-111X 
and frameshift P110+1 mutants did not inhibit antigen presentation, which would have 
been expected if the driving mechanism were stop codon read through (Figure 12 b).  On 
the other hand, the K353X mutation, which is very close to the C-terminus, did result in a 
substantial reduction in antigen presentation, suggesting that an alternative start site 
upstream of residue 353 may be responsible for epitope expression.  Unlike endogenous 
genome sequences, our OTC construct lacks an intron.  Since an intronic sequence is 
required for eukaryotic NMD (Chang, Imam et al. 2007, Isken, Kim et al. 2008, Lykke-
Andersen and Jensen 2015), we created constructs that inserted a mouse intron at amino 
acid 180 (Figure 18 a) and observed mRNA levels using RT-PCR of total RNA harvested 
from transfected 293 cells (Figure 18 b).  We also performed an antigen presentation 
assay using the intron-containing constructs (Figure 18 c).   
Despite a non-significant trend of reduced RNA levels in those intron-containing 
constructs with a PTC (Figure 18 b), significant levels of SIINFEKL-specific T cell 
activation were still observed for both wild-type and mutant intron-containing constructs 
(Figure 18 c).  Thus, NMD did not appear to inhibit the C-terminal translation and MHC 
loading of the SIINFEKL epitope. We cannot rule-out NMD reducing hOTC mRNA 
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levels from endogenous transcipts to a point that would eliminate the impact of read-
through or downstream translation. 
To assess the location of the alternative start site, we generated a new series of 
constructs by mutating each of the in-frame methionine codons located downstream of 
C109X into a stop codon, while retaining the C109X mutation.  Except for the construct 
containing the most downstream mutation (M338X), antigen presentation was observed 
in all other methionine-to-stop mutation constructs ( 
Figure 12 c).  This finding indicates that the alternative start site is between 
residues M335 and M338.  As no strong alternative start sites are predicted here, it is 
possible that the final methionine at residue 338 or an unconventional in-frame start site 
in this region initiates protein synthesis residues. However, we found that T cell 
activation still occurs if we mutate individual methionine residues (data not shown) or all 
methionine residues ( 
Figure 12 d) to arginine, indicating that at least one of the driving alternative start 
site is non-canonical.  While these studies do not precisely map the most distal start site 
capable of initiating translation it appears distinct from, but in close proximity to, the 
most distant methionine.  
To directly confirm expression of protein sequences downstream of C109X, we 
replaced the SIINFEKL tag with a strep-tag II and affinity purified hOTC fusion protein 
from plasmid transfected 293 cells. Tandem LCMS of tryptic digests of these samples 
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identified multiple hOTC derived peptides from hOTCco-C109X-StrepII transfected cells 
and no hOTCco-C109X-StrepII derived peptides from GFP-transfected cells (Table 2).  
All hOTC derived peptides detected by LC/MS were distal to the C109X mutation 
(Figure 13); total coverage of the gene downstream of the stop codon was 63. 
Epitopes downstream of a stop codon can activate immune responses in vivo 
We hypothesize that, with the help of appropriate inflammatory signals, antigen 
presentation from our PTC mutant constructs could also induce a CD8
+
 T cell response to 
the C-terminal SIINFEKL epitope in vivo.  Other groups have shown that viral vectors 
can be used to investigate expression of epitopes via read through, and we adopted a 
similar approach (Goodenough, Robinson et al. 2014).  We packaged into an adenoviral 
vector our most immunogenic PTC mutant (hOTCco-C109X-SIINFEKL), and 
immunized IM C57Bl/6 mice.  Our results demonstrate a T cell response to SIINFEKL in 
the context of the C109X stop codon that was as robust as that observed for the wild-type 
Ad5.hOTCco-SIINFEKL positive control (Figure 14).  No T cell activation to SIINFEKL 
was observed in mice immunized with Ad5.nLacZ, the negative control. 
Expression of an epitope downstream of the PTC induces peripheral tolerance in 
vivo 
A potentially interesting extension of our observations is that expression of 
epitopes in genes containing a PTC could induce peripheral or central tolerance if 
presented to T cells in the appropriate stage of their maturation cycle.  Previous research 
has shown that peripheral tolerance to a foreign protein or epitope can be achieved by 
 59 
 
expressing it in the liver using an AAV vector (Lin, Hensley et al. 2007).  The in vivo 
model system we used to study the induction of AAV mediated tolerance is as follows: 
AAV vector expressing wild type or one of three hOTCco-SIINFEKL mutants was 
injected IV into mice; 14 days later the animals were infused IV with an Ad vector 
expressing hOTCco-SIINFEKL) (Figure 15 a). As expected, administration of the 
AAV8.TBG. hOTCco-SIINFEKL vectors alone (wild type or mutants) did not elicit T 
cell responses to the SIINFEKL or Ad5 epitopes. Administration of the Ad5 vector 
without antecedent AAV vector administration did elicit robust T cell responses to both 
SIINFKL and Ad5 hexon confirming the potential immunogenicity of the Ad vector. 
Exposure of mice to AAV vectors expressing wild type and mutant hOTCco alleles 
(C109X, R141X and E154X) eliminated or statically significantly reduced the Ad 
induced response to SIINFEKL without affecting the response to Ad hexon in much the 
same way that the AAV vector expressing wild type hOTCco did. This indicates that 
sufficient expression of the SIINFEKL epitope occurs downstream of the PTC mutation 
to allow for induction of tolerance to it.  
Tolerance from AAV administration and transgene expression in the liver has 
been attributed to one of several mechanisms such as anergy or suppression driven by 
CD25
+
CD4
+
 regulatory T cells (Dobrzynski, Fitzgerald et al. 2006).  For regulatory T 
cells to play a role, there needs to be shared CD4
+
 epitopes between the tolerizing AAV 
vector and the immunizing vector; the only shared sequence capable of eliciting a CD4
+
 
T cell response in the system described above is hOTCco.  We eliminated the shared 
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hOTCco sequence while retaining the shared CTL epitope SIINFEKL by immunizing 
mice with an Ad5 vector containing cytoplasmic-targeted chicken ovalbumin, instead of 
the Ad5.hOTC-SIINFEKL vector, after exposure to the tolerance inducing 
AAV8.hOTCco-SIINFEKL vector. SIINFEKL would be the only overlapping peptide 
sequence expressed by both the AAV and Ad5 vectors, and therefore would be 
insufficient to generate a CD25
+
CD4
+
 T cell response specific for hOTC.  Interestingly, 
we continued to observe the reduction of T cell activation in groups receiving 
AAV8.hOTCco-SIINFEKL wild-type or mutant vectors compared to AAV8.hOTCco, 
AAV8.nLacZ, or no AAV8 vector controls when the immunizing vector was Ad 
expressing ovalbumin (Figure 15 b). This suggests that anergy plays a role in the 
induction of tolerance to epitopes downstream of a PTC although a component of Treg 
induced suppression cannot be ruled-out.  The observation of AAV induced tolerance to 
an antigen downstream of a PTC, as demonstrated by a reduction of Ad5 induced IFN ɣ 
ELISPOT, was confirmed using tetramer staining for SIINFEKL specific T cells (Figure 
15 c).  We repeated the previous experiment this time including two new AAV vectors 
based on previously used mutant constructs M338X and K353X both which lacked the 
ability to stimulate T cell in antigen presentation assays.  (Figure 16).  While neither 
allowed for as robust response as the control no AAV administration group, the responses 
were significantly higher than hOTC-SIINFEKL and equivalent to the non-specific 
control OTC.  Based on these results, it appears that alternative start site expression can 
result in tolerance to epitopes downstream of a PTC via a mechanism that likely involves 
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anergy although other redundant pathways such as regulatory T cell activation could 
contribute.  
Discussion 
Antigen presentation has a profound impact on shaping immune tolerance, where 
location, cell type, and the cytokine milieu can all vary the outcome (Thompson and 
Thomas 2002, Lee, Epardaud et al. 2007, Hadeiba, Lahl et al. 2012, Riedhammer and 
Weissert 2015).  A point of controversy in the field is the question of which antigen 
source has the most impact on antigen presentation and tolerance (Yewdell, Anton et al. 
1996, Dolan, Li et al. 2010, Dolan, Li et al. 2011, Croft, Smith et al. 2013): full-length 
proteins that are degraded by the proteasome (Colbert, Farfan-Arribas et al. 2013), or 
defective ribosomal initiation products that were initially discovered in viral presentation 
pathways, and later observed in mammalian translation (de Verteuil, Granados et al. 
2012). In fact, Shastri and colleagues suggested that non-conventional translation leading 
to expression cryptic peptides contributes substantially to the repertoire of peptide loaded 
MHC molecules (Starck and Shastri 2011, Starck, Jiang et al. 2012, Starck and Shastri 
2016, Vilborg and Steitz 2016). Transcription of substantial portions of the genome not 
thought to be involved in traditional translation could expand the scope and complexity 
of the MHC I/peptide repertoire. Previously, the field of gene therapy assumed that the 
complete absence of full-length protein expression due to null mutations results in a loss 
of tolerance via lack of antigen presentation (Mendell, Campbell et al. 2010).  However, 
studies have documented differences in immune responses following gene therapy 
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between true nulls that lack the gene entirely, compared with expected nulls caused by 
nonsense mutations (Cao, Hoffman et al. 2009).  As nonsense mutations may still lead to 
truncated, non-functional proteins, this finding was hypothesized to result from epitopes 
upstream of the nonsense mutation, which has been supported by recent work (Apcher, 
Daskalogianni et al. 2011).   
Interestingly, in the present study, we show that nonsense mutations in the OTC 
gene do not prevent expression and presentation of downstream peptides that could result 
in a more immune-tolerant phenotype in the OTC-targeted gene therapy setting.  First, we 
demonstrated that a SIINFEKL epitope downstream of nonsense mutations was still 
presented at a high enough efficiency in vivo to stimulate a SIINFEKL-specific T cell 
response.  We hypothesized that this finding could be due to two potential mechanisms: 
a) read-through of the stop codon by the incorporation of cognate tRNA, which could 
allow for the generation of the downstream epitopes (Goodenough, Robinson et al. 2014) 
or b) the presence of alternative start sites that could allow for translation initiation 
downstream of the stop codon and synthesis of the SIINFEKL antigen (Kochetov 2008, 
Bazykin and Kochetov 2011).  Using a second panel of hOTCco-SIINFEKL mutants, we 
determined that a high degree of antigen presentation and T cell activation still occurred 
in the presence of both a triple-stop mutant (i.e. CPL109-111X), as well as a construct 
with a frameshift mutation (i.e. P110 +1).  As stop codon read-through would have 
resulted in reduced or ablated expression of epitopes downstream of the triple-stop and 
frameshift mutations, respectively, our results suggested that alternative start sites were 
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responsible for driving C-terminal antigen presentation in this model.  Furthermore, the 
Met-to-stop mutants in this system suggested the presence of multiple start sites that were 
able to continue driving translation downstream of the PTC.  By mutating all methionine 
residues in the sequence, we also demonstrated that at least one non-canonical start 
appears to be involved. The fact that T cell activation was lost when a PTC mutation was 
introduced very close to the C-terminus of the protein indicates that there we no viable 
alternative translation initiation sites downstream of this mutation. With the use of two 
viral vector systems in a mammalian model of OTC deficiency (i.e., AAV to induce 
tolerance and Ad to activate immunity), we were able to confirm the induction of 
tolerance to epitopes downstream of nonsense mutations in the OTC gene as the result of 
anergy although other mechanisms of tolerance such as suppression by Tregs could not 
be ruled-out. In addition we reconfirmed that position of the mutation that seems to be 
important in allowing for antigen presentation as PTC closer to the c-terminus inhibited 
both antigen presentation and tolerance induction. 
Together, these findings suggest that the lack of immune tolerance to a variety of 
mutations that prevent protein expression could be overcome by the presence of an 
alternative translational start site allowing for expression in primary lymphoid organs and 
resultant central tolerance.  An important practical implication of this work relates to the 
relevance of the patient’s genotype in assessing the risk of pathologic adaptive immune 
responses in the setting of in vivo gene therapy. Patients with PTC mutations may not be 
as susceptible to CTL responses as are those patients with large deletions. We do not 
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believe that there exists enough evidence to exclude patients with PTC mutations from 
participating in gene therapy trial due to the theoretical risk of T cell mediated immunity. 
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Figure 11.  In vitro antigen presentation of epitopes downstream of reported OTC 
gene mutations. 
(A) Depicted is a schematic of the hOTC open reading frame. Mutant hOTCco-SIINFEKL constructs were 
generated using site-directed mutagenesis, such that each mutation would lie upstream of the inserted 
Ova257–264 (SIINFEKL) epitope.  Mutations were selected from previously reported human occurrences 
(Supplemental Table I).  Nonsense mutations are shown in bold.  (B) Antigen presentation of mutant 
hOTCco-SIINFEKL constructs in vitro.  MC57G mouse fibroblast cells expressing MHC H-2Kb were 
transfected with plasmid containing wild-type or mutant hOTC-SIINFEKL constructs in triplicate.  Cells 
were used to stimulate splenocytes from OT-1 mice in an IFN- ELISPOT assay.  Presented is the 
activation of IFN-
6
 splenocytes for various constructs as well as cells 
only (“Cells”), cells transfected with a GFP expressing construct (“GFP”) and cells activated with a 
combination of phorbol 12-myristate 13-acetate (PMA) and inomycin (IONO).  Equivalent results were 
obtained from two independent experiments with three replicates per experiment. ***p<0.0001. WT, wild 
type hOTCco construct. NS: non-significant. 
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Figure 12  Alternative start sites enable expression of epitopes downstream of 
nonsense mutations. 
 (A) Diagram showing within the hOTC open reading frame the location of new mutations designed to 
elucidate the mechanism of C-terminal expression.  (B – D) MC57G mouse fibroblasts were transfected in 
triplicate with plasmids containing a control transgene (“GFP”), hOTCco-SIINFEKL wild-type, or the 
hOTCco-SIINFEKL mutant plasmids.  Cells were then cultured with stimulated OT-1 splenocytes in an 
IFN- ELISPOT assay. An additional control was only cells (“Cells”).  Presented is the activation of IFN-ɣ 
expressing T cells in SFU/1x10
6
 splenocytes for various constructs as well as the Cells and GFP controls.  
This experiment was independently performed five times (B) hOTCco-SIINFEKL constructs included 
CPL109-111X, P110+1, and K353X mutants.  (C) Antigen presentation assays for a series of Met-to-stop 
substitutions were performed to locate the alternative start site. Each construct includes a single Met-to-stop 
mutation in a hOTCco gene that has a C109X mutation. (D) Antigen presentation using a construct with all 
methionines downstream of C109X substituted to arginine to determine the alternative start site.  These 
experiments were independently performed twice. **p<0.001, ***p<0.0001 in comparison with cells only 
and GFP negative controls. 
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Figure 13  Amino acid coverage of C109X and unique amino acid sequences 
detected in samples expressing hOTCco-C109X-StrepII.   
HEK 293T cells were transfected with either hOTCco-C109X-StrepII or control eGFP plasmid constructs.  
Cells were grown for 24 h post transfection, and peptides were isolated by column chromatography.  Eluted 
peptides were submitted to mass spectrometry analysis.  Detected peptides that localized to OTC are 
highlighted in alternating black and underlined dark grey.  Light grey amino acids were not isolated within 
a peptide. 
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Figure 14  In vivo activation of endogenous T cells to an epitope downstream of the 
PTC.   
C57Bl/6 mice (n = 3) were immunized IV with 5x10
10
 particles of Ad5 vector containing either wild-type 
hOTCco-SIINFEKL, hOTCco-C109X-SIINFEKL, or nLacZ.  Day 10 after immunization, mice were 
sacrificed and splenocytes were harvested for an IFN- ELISPOT assay.  Cells were stimulated with either 
media, SIINFEKL peptide, or Ad5 hexon. Presented is the activation of IFN-ɣexpressing T cells in 
SFU/1x10
6
 splenocytes. NS, not significant in comparison with Ad5.nLacZ control. 
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Figure 15  In vivo tolerance induction to epitopes downstream of the PTC.   
(A – C) C57Bl/6 mice (n = 3/group) were administered IV with AAV8 vectors expressing different 
hOTCco genes or a no-AAV8? vector control.  At day 14, mice were immunized with either (A) 
Ad5.hOTCco-SIINFEKL or (B, C) Ad5.OVA, which naturally contains the SIINFEKL epitope.  At day 27, 
mice were sacrificed and splenocytes were harvested for either (A, B) IFN- ELISPOT assays or (C) CD8 
tetramer staining.  ( A, B) cells were stimulated with media (black),  SIINFEKL (white), or Ad5 Hexon 
(grey).  (C) the lymphocyte population was gated by forward and side scatter, and then gated by CD8 
staining.  The percent of SIINFEKL-specific T cells within the CD8
+
 population was determined by 
tetramer staining.  Presented for panels A and B is the activation of IFN-ɣexpressing T cells in SFU/1x106 
splenocytes. (C) is the percent of CD8+ T cells that are tetramer positive. These experiments were 
independently performed twice.  *p<0.05, **p<0.001, ***p<0.0001 in comparison with no-AAV vector 
negative control. 
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Figure 16  PTC near C-terminus inhibits in vivo tolerance induction to epitopes 
downstream of mutation. 
C57Bl/6 mice (n = 4) were administered IV with AAV8 vectors expressing different 
hOTCco genes or a no-AAV vector control.  At day 14, mice were immunized with 
Ad5.OVA, which naturally contains the SIINFEKL epitope.  At day 27, mice were 
sacrificed and splenocytes were harvested for IFN- ELISPOT assay.  Cells were 
stimulated with media (black),  SIINFEKL (white), or Ad5 Hexon (grey).  Presented for 
is the activation of IFN-g expressing T cells in SFU/1x10
6
 splenocytes. These 
experiments were *p<0.05, **p<0.001, ***p<0.0001 in comparison with OTC-
SIINFEKL vector positive control. NS: non-significant. SFU: spot forming units 
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Table 1  Private mutations selected to give a range of mutation types, including 
nonsense, missense, and splice variants resulting in exon-skipping. 
Mutation Codon 
Nucleotide 
change Exon/Intron Gender Age 
OTC 
Activity Reference 
Missense R26Q CGG>CAG Exon1 Male 4 days 0% 
Grompe et al., 
1989, PNAS 
Reduced 
activity/late 
onset L88N A>T Exon 3 Male 4 months 23% 
Oppliger et al., 
1996, Hum 
Mutat 
Nonsense C109X T>A Exon 4 Male 3 days ND 
Calvas et al., 
1998, Hum 
Mutat 
Nonsense R141X CGA>TGA Exon 5 Male Neonatal 0% 
Oppliger et al., 
1996, Hum 
Mutat 
Nonsense Q154X GAA>TAA Exon 6 ND ND ND 
Grompe et al., 
1989, PNAS 
Missense P225L CCG>CTG Exon 7 Male 4 days 2% 
Matsuda and 
Tanake, 1997, 
Am J Med 
Genet 
Reduced 
activity/late 
onset T264A ACT>GCT Exon 8 Male 5 months 22% 
Matsuda and 
Tanake, 1997, 
Am J Med 
Genet 
Missense H302Y CAC>TAC Exon 9 Male Neonatal 0% 
Oppliger et al., 
1996, Hum 
Mutat 
Exon-
skipping - GT > GC Intron 7 Male ND ND 
Carstens et al., 
1991, Am J 
Med Genet 
ND, not determined 
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Figure 17 hOTC codon sequence and transfection control  
(A) MC57G mouse fibroblasts were not transfected (“Cells”) or transfected with plasmids containing a 
control transgene (“GFP”), codon optimized wild-type amino acid sequence hOTCco-SIINFEKL, codon 
optimized mutant amino acid sequence hOTCco-SIINFEKL, native codon wild-type amino acid sequence 
hOTC-SIINFEKL, or native codon mutant amino acid sequence hOTC-SIINFEKL plasmids. Cells were 
then cultured with stimulated OT-1 splenocytes in an IFN-ɣELISPOT assay (B) MC57G mouse fibroblasts 
were either not transfected or transfected with plasmids containing a control transgene (GFP), wild-type 
hOTCco-SIINFEKL, or mutant hOTCco-SIINFEKL plasmids with or without Lipofectamine. Cells were 
then cultured with stimulated OT-1 splenocytes in an IFN-ɣELISPOT assay. Presented is the activation of 
IFN-ɣ expressing T cells in SFU/1x106 splenocytes for various constructs as well as the Cells and GFP 
controls. Experiments were independently performed twice and in each experiment the individual groups 
were evaluated in triplicate. ***p<0.0001 in comparison with cells only and GFP negative controls. SFU: 
spot forming units. 
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Figure 18  Impact of intronic sequence on mRNA expression and antigen 
presentation. 
 (A) Diagram showing the location of the intron that is 78 bp downstream of E154X. (B) RT-qPCR analysis 
was conducted in 293 cells transfected with wild-type or mutant plasmid constructs and is presented as 
OTC cDNA’s per 500 ng RNA. (C) MC57G mouse fibroblasts were transfected in triplicate with plasmids 
containing wild-type hOTCco-SIINFEK-Intron, or mutant hOTCco-SIINFEKL intron constructs. Cells 
were then cultured with stimulated OT-1 splenocytes in an IFN ɣ ELISPOT assay. Presented is the 
activation of IFN-g expressing T cells in SFU/1x10
6
 splenocytes for various constructs as well as the Cells 
and GFP controls. Both experiments were independently performed twice, n=3 mice / group. ***p<0.0001 
in comparison with cells only negative control. NS, not significant 
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Table 2  Peptide identification using LC/MS with affinity-purified samples 
expressing GFP or hOTC-C109X-StrepII. 
Algorithm Sample OTC Peptides Identified Reads
a
 E-Value 
Xtandem! C109X 9 54 -394 
Xtandem! GFP - - - 
 
a
Number of total reads in the sample that align to the OTC sequence. 
 79 
 
Chapter 4 
 Influence of Vector on Anti-Transgene Antibody Formation Following AAV-
Mediated Gene Therapy 
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Abstract 
Antibody formation to secreted transgene products remains as a potential barrier to many 
gene therapies.  Driven by exposure of naïve B cells to a transgene product and the 
immune stimulus of vector administration, expression can result in an adaptive immune 
response and antibody formation against the therapeutic protein resulting in attenuation 
of efficacy.  Here, we show that TLR9 signaling and the expression location profile is 
involved in driving the activation of B cells against secreted protein alpha-L-iduronidase 
(IDUA), following AAV administration.  This TLR9-dependent response occurs  
independently of transgene CpG content, however it is strongly influenced by the 
location of transgene expression or lack therefore of.  Overall, our results suggest that 
TLR9 signaling is important for the development of adaptive immune responses to 
transgene products following AAV gene therapy, and that elimination of CpG motifs in 
the vector genome may not be sufficient to prevent TLR9 activation. 
Introduction 
Adeno-associated virus (AAV) vectors have been investigated in many diseases 
where cross correction of transgene product expressed into the blood is vital for 
therapeutic efficacy.  In many of these preclinical models, antibody formation to the 
transgene product has been observed.  However, the adaptive immune response is tightly 
controlled; exposure to a novel protein often results in tolerance rather than immunity, 
unless an inflammatory signal is present to initiate an adaptive immune response to the 
novel antigen (Lang, Georgiev et al. 2006).  One potential immunogenic stimulus 
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associated with AAV-mediated gene therapy is the vector genome.  The immune 
system’s major sensing agent for this foreign material is TLR9, located in the endosomal 
compartment, which recognizes unmethylated CpG DNA and induces pro-inflammatory 
reactions that can result in an adaptive response (Hemmi, Takeuchi et al. 2000, Rogers, 
Martino et al. 2011).  Additional work has been done to avoid TLR9-induced 
inflammatory signaling by CpG depletion or by increasing the CpG methylation state in 
DNA-based therapies (Reyes-Sandoval and Ertl 2004, Faust, Bell et al. 2013, Shapir, 
Miari et al. 2015).  However, there is evidence that TLR9 binds the phosphodiester 
backbone of DNA regardless of the nucleotide sequence, and that activation is merely 
enhanced by CpG motifs (Haas, Metzger et al. 2008).   
The involvement of TLR9 signaling following intramuscular (IM) AAV administration 
has been found to be important in the generation of both anti-transgene antibodies and 
AAV neutralizing antibodies (Zhu, Huang et al. 2009, Rogers, Suzuki et al. 2015).  TLR9 
signaling was shown to have a more limited role in the production of anti-transgene 
antibodies following intravenous (IV) vector administration, with myeloid differentiation 
primary response gene 88 (MyD88) being required to generate this immune response 
(Rogers, Suzuki et al. 2015).  A tolerizing phenomenon has been observed following 
hepatic gene transfer using AAV vectors expressing the serine protease factor IX, leading 
to reduced or ablated anti-transgene antibodies (Cao, Dobrzynski et al. 2007), and even 
elimination of existing transgene antibodies in large animal studies (Finn, Ozelo et al. 
2010, Crudele, Finn et al. 2015).  However, our experience with different monogenetic 
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disorders indicates that this phenomenon is transgene-dependent (Hinderer, Bell et al. 
2015).  AAV-mediated hepatic gene therapy for mucopolysaccharidosis I (MPS I) in a 
dog model provoked an antibody response to the transgene product, alpha-L iduronidase 
(IDUA), demonstrating that hepatic expression alone is insufficient to induce tolerance 
(Hinderer, Bell et al. 2015).   
In this study, we investigated the influence of TLR9 and transgene expression on 
antibody formation following AAV gene therapy using different routes of administration, 
primarily focusing on systemic delivery.  We found a role for TLR9 in anti-transgene 
antibody formation against human IDUA (hIDUA) following IV vector administration; 
this response was also modified by the promoter.  Unexpectedly, CpG depletion of the 
transgene did not influence the immune response to IDUA.  Further, we discovered a link 
between generation of anti-IDUA antibodies and tissue restricted expression.  These 
findings suggest that, while TLR9 activation can be consequential in eliciting a transgene 
specific adaptive immune response, our ability to curb its influence may be limited. 
Methods 
Vectors 
AAV9 hIDUAco (human codon-optimized IDUA under the control of a CMV, CB7, or 
EF1alpha enhancer/promoter containing SV40 poly A) was produced along with other 
AAV vectors using an iodixanol step gradient (Lock, Alvira et al. 2010).   
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Mouse Anti hIDUA Detection Assay 
Clear, flat-bottom polystyrene high-binding plates were coated with 50 μl/well of 0.58 
mg/kg Aldurazyme (Biomarin, San Rafael, CA) diluted 1:100 in pH 5.8 PBS.  Plates 
were washed five times using 0.05% PBS-Tween solution and then blocked for two hours 
with 2% BSA (GE Healthcare, Little Chalfont, UK) diluted in pH 5.8 Dulbecco’s PBS 
(Thermo Fisher Scientific, Waltham, MA).  Serum was diluted 1:1,000 in Dulbecco’s 
PBS (Thermo Fisher Scientific, Waltham, MA); 50μL of diluted sample was plated and 
incubated at room temperature for two hours.  Positive serum for the standard was diluted 
1:10 and then diluted four fold for a series of seven dilutions and a negative control well.  
Plates were washed as previously described.  Streptavidin-conjugated goat anti-mouse 
IgG antibody (BD Biosciences, San Jose, CA) was diluted 1:10,000 in 2% BSA (GE 
Healthcare, Little Chalfont, UK), and 100μl of diluted goat anti-mouse IgG antibody was 
added per well.  Plates were incubated for 1 hour and washed as previously described.  
150μl of TMB solution was added per well.  Plates were read up to 20 minutes after 
adding stop read value to 450 nm. 
IDUA Activity Assay 
4-MU substrate (Glycosynth, Winwick Quay, Warrington, UK) was diluted 1:25 in 
IDUA assay buffer (0.1 M sodium acetate, 0.15 M NaCl, 0.05% TritonX, pH 3.8).  In 96-
well flat bottom tissue culture plates, 95 ul di-H20, 100 ul diluted 4-MU substrate, and 5 
µl serum sample was added to wells in duplicate.  Plates were sealed, gently shaken, and 
incubated at 37 ºC for 2 hours.  180 µl IDUA stop buffer (0.29 M glycine, 0.18 M sodium 
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citrate, pH 10.9) was added per well.  20 µl sample was removed to black well plates 
(Corning, Corning New York) for fluorescence readings (365 nm excitation and 450 nm 
emission). 
ELISPOT 
Mice were administered IM 2x10
11
 GC of AAV9 expressing either hIDUA or a CpG-
depleted variant in 50 µl PBS.  On day 14 after vector administration, mice were 
sacrificed and splenocytes were harvested, as previously described (Limberis, Figueredo 
et al. 2007).  Interferon ɣ ELISPOT assays were performed, according to the 
manufacturer’s instructions (BD Biosciences, San Jose, CA).  Cells were seeded at a 
concentration of 2x10
5
 or 2x10
4
 cells/well along with 2 ug/ml peptide pool A, B, or C of 
an overlapping 15-mer peptide library spanning the full-length hIDUA (Mimotopes, 
Victoria, Australia).  Splenocytes were incubated at 37 °C in 5% CO2 for 18 hours.  Spots 
were counted using the AID ELISPOT Reader System (Cell Technology, Columbia, 
MD). 
Results 
Previously we  demonstrated that TLR9 signaling is capable of triggering a strong 
CTL response to transgene product following AAV-mediated gene therapy. We next 
investigated its ability to modulate a humoral response.  C57BL/6 or TLR9 KO mice 
were given IV AAV9.hIDUAco under the control of one of three promoters: the universal 
promoters CMV or CB7, or the liver-specific promoter TBG (Bell, Wang et al. 2011).  
We determined transgene product expression by measuring hIDUA activity in serum, 
 85 
 
which inversely correlated with the presence of antibodies for all three groups.  AAV9 
vectors with either universal promoter (CMV or CB7) triggered the production of a 
robust anti-hIDUA antibody that reduced serum activity (Figure 19 a, b); in contrast, 
TBG-driven expression resulted in low anti-hIDUA antibody levels and a high, consistent 
serum activity level (Figure 19 c).  However, in the TLR9 KO mice, vectors with the 
universal promoters CMV or CB7 had dramatically reduced antibody generation to 
hIDUA, indicating that TLR9 signaling is required for the anti-transgene response 
(Figure 19 a, b). 
To further investigate the role of TLR9 signaling in IDUA-specific responses, we 
administered 1x10
11
 GC AAV9.hIDUAco IV or IM under the control of either the CMV 
or the CB7 promoters to either C57BL/6 or TLR9 KO mice.  After ten days, we 
sacrificed the mice and performed an IFN-ɣ ELISPOT on splenocytes.  As we 
anticipated, T cells from TLR9 KO mice stimulated with hIDUA pools did not respond as 
robustly as those from C57BL/6 mice across all treatment regimens (Figure 20 a, b).  
Interestingly, the largest response occurred in mice given AAV9.CB7.hIDUAco IV 
compared to IM; CMV-containing vectors had an overall lower T cell response (Figure 
20 a, b) corresponding with an overall lower peak activity.  TLR9 signaling is thought to 
be important for proper B-cell development (Hua and Hou 2013).  To confirm that the 
observed effect was due to loss of TLR9 signaling upon administration of vector and not 
an intrinsic defect in the B cells, we adoptively transferred 1.5 x 10
7
 B cells from 
C57BL/6 mice or TLR9 KO mice into muMt
-
 mice that lack mature B cells.  One week 
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later, we administered 1x10
11 
GC AAV9 CMV.hIDUAco IV and monitored serum for 
transgene activity and transgene-specific antibody expression (Figure 21 a).  We found 
that B cells from both groups were capable of producing anti-transgene antibodies and 
ablating serum transgene activity levels, indicating that the absence of TLR9 signaling in 
B cells did not inhibit these immune responses (Figure 21 b). 
  We next assessed whether modulating the CpG content would influence the 
antibody response to hIDUA, as we found previously removal of CpG content can reduce 
T cell responses in the muscle to a reporter transgene (Faust, Bell et al. 2013).  We 
utilized an AAV vector with the hIDUAco transgene under the control of an EF1-α 
promoter depleted of CpGs.  We designed a second transgene construct in which the 
hIDUA transgene was depleted of CpG content while retaining the amino acid sequence; 
we confirmed that the activity of the construct was not changed due to codon effects 
using an in vitro activity assay (Figure 22 a).  We administered mice with vectors AAV9 
EF1-α.hIDUAco or EF1-α.hIDUA,CpG- either IV or IM, and assayed IDUA activity and 
antibodies from serum for each cohort (Figure 23 a, b).  IDUA activity peaked at day 7 
and remained steady throughout the study in both groups (Figure 23 a, b).  Anti-IDUA 
antibodies rose steadily throughout the experiment in both groups, but did not inhibit 
IDUA activity or reach levels as high as those measured when AAV9.CMV. hIDUAco or 
AAV9.CB7.hIDUAco was administered (Figure 23 a, b; Figure 19 a, b).  To confirm that 
CpG depletion did not impact the cytotoxic immune response to IDUA, which would 
otherwise reduce transgene activity, we examined CTL activation.  We administered 
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mice with either 1x10
11
 AAV9.EF1-α.hIDUAco or AAV9. EF1-α.hIDUA.CpG- IM 
vector, and ten days later performed IFN-ɣ ELISPOT on splenocytes.  T cell responses to 
IDUA were detectable following IM or IV vector administration; however, we did not 
observe a difference between groups in the magnitude of the response, indicating 
effective T cell activation regardless of transgene CpG content (Figure 23 c). 
Finally we examined the differences in antibody formation and transgene 
expression mediated by promoter restriction.  As shown earlier, CMV expression results 
in both low serum activity and high antibody titer as opposed to TBG driven expression.  
When AAV9.CMV.hDUA and AAV9.CB7.hDUA are mixed 1:1 and administered serum 
activity peaks and then reduces by 2 fold corresponding with a rise in antibody titer that 
is similar to mice injected only with CMV containing vectors (Figure 24 a).  There is 
evidence in mice that muscle cells express MHC II under inflammatory conditions and 
allow for priming of CD4+ T cells, which is a crucial step for the ultimate activation of B 
cells (Keller, Fokken et al. 2011, Faust, Bell et al. 2013).  To reduce muscle expression 
we cloned four miR206 sequences, that target mRNA in skeletal muscle for degradation, 
into the poly A section of our CB7.hIDUA which has both initial high expression 
followed by a robust antibody increase and loss of serum expression (Greig, Peng et al. 
2014).  Mice injected with the AAV9.CB7.hIDUA.4xmiR206 maintained higher 
expression and lower antibody titer until the last time point of the study where it 
converged with control group; despite this the activity did not decrease (Figure 24 b). 
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Discussion  
Here we considered the influence of TLR9 and other host factors on humoral 
responses. For these experiments, we could not use OTC as the transgene, as it would 
likely be sequestered in the mitochondria and not come into contact with B cells.  Instead, 
we used a vector expressing hIDUA, a secreted transgene that caused antibodies to form 
against it in our previous studies in both MPS1 -/- and C57BL/6 mice.  Indeed, we saw 
differences in the relative titers of anti-hIDUA antibodies between constructs with 
expression driven by the universal promoters CMV and CB7 compared to the liver-
specific TBG promoter.  Other groups previously reported similar results when using a 
muscle-specific promoter (Doerfler, Todd et al. 2016).  Importantly, we demonstrated 
that a lack of TLR9 signaling dramatically reduced the anti-IDUA antibody response in 
mice that received either CMV or CB7 hIDUA vector, indicating that its signaling is 
critical for developing a robust humoral response following global expression.  
We next assessed the impact of TLR9 signaling, promoter selection, and route of 
administration on CTL responses.  We compared C57BL/6 or TLR9 KO mice that 
received AAV9.CMV.hIDUA or AAV9.CB7.hIDUA IV or IM.  We found that 
splenocytes isolated from TLR9 KO mice did not respond to stimulation with hIDUA 
peptide pools compared to C57BL/6 mice across all experimental conditions.  
Interestingly, the largest response occurred in mice that received AAV9.CB7.hIDUA IV 
compared to IM; CMV-containing vectors had an overall lower T cell response.  This 
could indicate that expression level is tied to the strength of immune activation, where the 
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high activity of CB7 and higher expression of the transgene product could enable better 
priming of APCs.  To further probe this observation, we reduced the CpG content of 
transgene, as we have done previously (Faust, Bell et al. 2013).  We used a universal 
promoter, EF1-α, as this was previously CpG depleted (Faust, Bell et al. 2013).  When 
given the vectors IV, groups that had retained our codon-optimized hIDUA sequence did 
not generate a higher antibody titer than those receiving CpG-depleted hIDUA.  
Surprising, both maintained high levels of serum IDUA activity.  The antibody titers 
were lower in mice that received vectors driven by EF1-α compared to CMV or CB7, 
suggesting that there is a threshold for transgene-specific antibody levels to negatively 
affect activity and that some inherent differences between CB7, CMV and EF1-α account 
for the gap in transgene-specific antibody and serum levels.  We next confirmed that CpG 
depletion did not impact transgene-specific immune responses, as measured by IFN-ɣ 
ELISPOT.  Although this result was consistent with our antibody data, it did contradict 
previous results in studies where we modified the CpG content of nuclear-targeted LacZ 
(Faust, Bell et al. 2013).  This difference could be explained by a number of factors, 
including the vector (in our previous work we used the more immunogenic AAVrh32.33 
(Mays, Vandenberghe et al. 2009)) or enhancement of the CpG content of the LacZ 
control transgene sequence (the depletion could have caused a decrease in pro-
inflammatory cytokines that was not capable of inhibiting larger responses to the 
transgene product). 
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Lastly, we investigated one aspect of how the site of expression can affect enzyme 
activity and potentially therapeutic efficacy.  To accomplish this we mixed hIDUA 
expressing AAV9 vectors driven by either CMV or TBG promoters.  We demonstrated 
that the dominant effect of CMV expression is high antibody titer capable of overcoming 
a presumed tolerogenic effect that liver driven AAV expression can induce (Cao, 
Dobrzynski et al. 2007, Hinderer, Bell et al. 2015, Doerfler, Todd et al. 2016).  It has 
suggested that one organ group where expression could positively influence antibody 
generation is skeletal which is capable of presenting on MHC II potentially priming 
CD4+ T cells for B cell activation (Keller, Fokken et al. 2011, Faust, Bell et al. 2013, 
Doerfler, Todd et al. 2016).  By eliminating muscle expression using miR206 sites in a 
CB7.hIDUA construct we were able to observe stable expression of the transgene product 
and a slower raise in anti-transgene antibodies.  An interesting observation was both 
CB7.hIDAU.miR206 and EF1α driven constructs reached an antibody titer elevated to 
levels that in CMV or CB7 containing vectors serum activity was dramatically reduced, 
yet in CB7.hIDAU.miR206 and EF1α they were able to maintain higher activity 
indicating that serum activity loss could be caused by factors beyond antibody titer. 
Together, these results demonstrate the importance of TLR9 in developing a 
robust humoral response to a secreted transgene product and highlight an important but 
complicated role for promoters.  While CpG depletion did not improve the outcome of 
AAV9 vector administration, this informed us that TLR9 signaling might be independent 
of CpG influence on our vector genomes.  This could be due to the natural DNA 
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backbone retaining a basal level of immunogenicity (Haas, Metzger et al. 2008).  Some 
groups have also reported the importance of methylation and its inhibition of TLR9 
binding; this potentially could be explored to rationally design vectors to be less 
immunogenic.  In larger animal models in which transgene antibodies seem to be more 
common, the effect of CpG depletion may become more pronounced.  Therefore, future 
studies may help to further our knowledge and ability to design less immunogenic 
vectors.  
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Figure 19 TLR9 Signaling is required for an anti-transgene antibody response.   
 Male C57BL/6 or TLR9 KO mice (n=5/group) age 6-8 weeks were given IV 1x10
11
 GC of (a) 
AAV9.CMV.hIDUA vector (b) AAV9.CB7.hIDUA vector promoter, or (c) AAV9.TBG.hIDUA vector.  
Mice were bled weekly, and IDUA activity and anti-transgene antibodies were determined from serum. 
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Figure 20 TLR9 Signaling is Required for an Anti-Transgene CTL Response. 
Male C57BL/6 or TLR9 KO mice (n=5/group) age 6-8 weeks were given 1x10
11
 IV  GC (a) or IM (b) 
AAV9 hIDUA vector with CMV or CB7 promoter.  Mice were sacrificed ten days later and INF-gamma 
ELISPOT was performed on isolated T cells.  Analysis was performed by one-way ANOVA with the 
Bonferroni test comparing columns in C57BL/6 mice to TLR9 KO mice for each stimulation., *P<0.05, 
**P<0.001, ***P<0.0001.  
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Figure 21 TLR9 KO B cells are intrinsically capable of mounting an anti-transgene 
response. 
(a) 1.5E7 B cells from C57BL/6 mice or TLR9 KO mice (n=5/group) were adoptively transferred to µMT 
mice.  One week later, mice were administered 1x10
11
 AAV9.CMV.hIDUA IV.  (b) Serum IDUA activity 
and anti-transgene antibodies were determined every seven days.
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Figure 22 CpG+ and CpG- sequences have equivalent activity in vitro. 
HEK-293 cells were transfected with plasmid containing EF1-Alpha.coCpG+.hIDUA, EF1-Alpha.coCpG- 
hIDUA, or CB7.coCpG+.hIDUA constructs in triplicate.  Media was collected before transfection and each 
following day for two days.  IDUA activity was assayed after collection of media. 
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Figure 23 CpG Depletion Does Not Inhibit Anti-IDUA Formation.   
Male C57BL/6 mice (n=5) ages 6-8 weks were given IV or IM 1x10
11
 AAV9 EF1α hIDUA vector with 
normal or CpG-depleted transgene sequence.  (a, b) IDUA activity and antibodies were determined from 
serum.  (c) T cell IFN-gamma ELISPOT was performed on splenocytes isolated from mice ten days after 
vector administration. 
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Figure 24 Suppression of Muscle Expression Increase Transgene Activity. 
Male C57BL/6 mice (n=5) ages 6-8 weeks were given IV 1x10
11
 of AAV9.hIDUA vector with CMV 
promoter, TBG promoter, or a dose of both. Serum IDUA activity and anti-transgene antibodies were 
determined every seven days.  (a) Results show that be expressing IDUA with a universal promoter anti-
body titer rises and serum IDUA activity lowers even when there is concurrent high levels of expression 
from the liver. (b) Male C57BL/6 mice (n=5) ages 6-8 weeks were given IV 1x10
11
 of AAV9.CB7.IDUA 
with or without a 4X miRNA 206 sequence.  Serum IDUA activity and anti-transgene antibodies were 
determined every seven days. 
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Chapter 5: Discussion 
General Summary 
AAV gene therapy holds promise for safe efficacious treatment of genetic disorders with 
limited available therapeutics.  Preclinical development in many disease models, 
including MPS1, hemophilia, muscular dystrophy, pompe disease, have both 
demonstrated efficacy and the potential for an immune response to AAV mediated gene 
therapy (Manno, Pierce et al. 2006, Mendell, Campbell et al. 2010, Hinderer, Bell et al. 
2015, Doerfler, Todd et al. 2016).  Following these observations and previous challenges 
with adenoviral vector immunogenicity studies we have investigated the immune 
response and its effect on gene therapy efficacy.  The goal of my dissertation work was to 
investigate the underlying host factors that modulate the activation of the adaptive 
immune response to the transgene product.  With deeper understanding of these agents 
we could better assess the risks of each new AAV clinical product and tailor AAV 
treatment based on an individual’s likelihood for immune activation.  Through these 
efforts, we may discover critical points in adaptive immune activation and lead to a safer 
more thought-out methodology for reducing the risk of adverse immunity to gene 
therapy.  
Gene Therapy, Immunology and TRL9 
Previous work performed in the Wilson laboratory had shown that CD8
+
 T cells 
required inflammatory signaling in addition to the presence of their specific antigen to 
become active and attenuate transgene expression of highly immunogenic bacterial 
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protein (Somanathan, Breous et al. 2010, Breous, Somanathan et al. 2011).  As described 
in chapter 2, I opted to develop a model to explore transgene-specific immunity against 
the mitochondrial protein OTC and to further investigate the influence of specific host 
factors that are critical to immune activation.  Initially I sought to develop a scheme 
similar to ones used previously to activate CD8
+
 T cells against a specific transgene by 
immunizing C57Bl/6 mice with Ad5 vector expressing hOTCco, then harvest the T cells 
for adoptive transfer (Somanathan, Breous et al. 2010).  Our first experiments did not 
yield the anticipated result, as T cell activation, measured by IFN-ɣ ELISPOT, did not 
induce a robust OTC-specific response immune response. Inducing and immune response 
required a more robust methodology, first we administered the immunogenic 
AAVrh32.33, then 12 weeks later administered both Ad5 and TLR9 agonist concurrent 
with vector and for three days following (Figure 2 a ,b) (Mays, Vandenberghe et al. 
2009).  These results indicated that we were not activating naive hOTC-specific T cells, 
but rather breaking tolerance of anergized T cells which could have occurred due to the 
highly conserved nature of OTC between species (P11725, P00480) (Lang, Georgiev et 
al. 2006). Under such stringent conditions necessary to generate a population of OTC-
specific CD8
+
 T cells I did not consider it feasible to continue with that methodology. 
Further, I opted against using cells that had previously been exposed to the transgene as 
this is not what I anticipate will occur in AAV gene therapy for the patients most likely to 
have an adverse T cell activation, namely, those that express no protein from the mutated 
gene.  To develop our model I took advantage of the transgenic OT-1 mouse which 
contains genes for a T cell receptor that specifically binds the immune-dominant epitope 
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of chicken ovalbumin (SIINFKEL) by generating a construct with a SIIFEKL tag 
attached to the c-terminus of hOTCco (Figure 11 a) (Hogquist, Jameson et al. 1994).  
Though the epitope tag did diminish OTC activity (Figure 3), biogenesis of the protein 
and its translocation to the mitochondria remained intact, which was important for our 
design study. Maintenance of the biogenesis pathway  was important since I expected 
protein degradation and processing into antigen to be similar to the untagged hOTCco 
(Yewdell, Reits et al. 2003).  To investigate the influence of TLR9 on the activation of a 
cell mediated immune response to the transgene product we packaged hOTCco-
SIINFEKL into an AAV8 vector (Figure 5).  C57Bl/6 mice were given IV either TLR9, 
OT-1 CD8
+
 T cells or both and analyzed for toxicity by evaluation of transaminase levels 
and the presence of genome copies four weeks after adoptive transfer.  Elevations of AST 
and ALT were only observed in the group of mice that received both transgene specific T 
cells and TLR9 agonist indicating a requirement for a naïve CD8
+
 T cell population, and 
TLR9 can provide the necessary inflammatory signals to activate a cellular response.  
Further, we observed both a transgene mRNA and genome copy loss indicating clearance 
of the episomes potentially driven by cell death. 
To evaluate the number of naïve T cells required to initiate such an immune 
response we titrated the number of CD8
+
 T cells that were adoptively transferred to 
recipient mice.  Surprisingly even at the lowest dose of 3,000 transferred cells we 
observed a rise in transaminase levels (AST and ALT) (Figure 6 a).  This low dose also 
resulted in a decrease of GC, although not as dramatic as that observed in the higher dose 
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groups. These findings were corroborated by our experiment designed to examine the 
activation of the adoptively transferred cells infiltrating the liver, in which the majority of 
cells were activated (Figure 9 d).  We investigated the importance of naïve T cells in 
developing a cell mediated response by withholding TLR9 agonist until three weeks after 
the adoptive transfer to allow for CD8
+
 OT-1 T cells to come in contact with the 
SIINFEKL antigen presented by liver cells.  While toxicity was reduced with 
transaminase elevation being substantially decreased in the late inflammation group; 
protein expression was not consistent between mice in the group despite genome copies 
and RNA expression being similar.  These findings suggest that antigen naïve T cells are 
able to generate a more robust immune response compared to T cells that have previously 
been exposed to a transgene product prior to an inflammatory event.   
Clearance of transduced cells by an adaptive immune response has been a concern 
for the development of AAV-based gene therapy; in our experiments we address this 
likelihood.  C57Bl/6 mice were given IV AAV8.TBG.hOTCco-SIINFEKL and fourteen 
days later administered CD8
+
 OT-1 T cells and TLR9 agonist.  Mice from this group and 
control groups were then sacrificed on days 3, 7 and 17 following adoptive transfer.  
Liver sections were analyzed for CD8+ T cell infiltration (Figure 8 a) noting extreme 
infiltration in the TLR9 treated group into regions beyond the periportal or pericentral 
regions.  We also observed some infiltration in the periportal liver region in mice 
administered only AAV8.TBG.hOTCco-SIINFEKL and T cells indicating some homing 
to the liver but potentially no activation.  Death markers capsase9 and TUNEL staining 
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were performed on liver sections, however, no differences were observed between groups 
including a control AAV8.TBG.hOTCco-SIINFEKL only treated cohort.  The possibility 
that we missed the time-point of maximal cell death led us to using a marker for cell 
growth KI-67 to evaluate the regeneration of the liver (Figure 8 b). Upon examination we 
observed a large percentage of hepatocytes marked as having left G0 of the cell cycle in 
mice that received TLR9 agonist indicating that active division was occurring to replace 
cells lost as a consequence of the immune response.  Further, we observed significant GC 
loss in TLR9 treated mice corroborating our KI67 data suggesting that transduced cells 
were lysed by the infiltrating CD8
+
 T cells (Figure 8c).  Whereas previous loss of 
transgene expression was not highly correlated with loss of GC and was potentially 
caused by shut-off of transcription, here we have evidence that massive cell death can 
occur prior to regeneration of hepatocytes (Somanathan, Breous et al. 2010, Breous, 
Somanathan et al. 2011).    
To confirm that the adoptively transferred T cells were migrating to the liver, 
mice were given IV AAV8.hOTC.SIINFEKL.  Fourteen days later, mice were 
administered TLR9 and CFSE labeled CD8
+
 OT-1 T cells. Seven days following 
adoptive transfer, at peak liver infiltration, mice were sacrificed and liver and spleen were 
harvested for lymphocyte isolation.  In mice receiving TRL9 agonist, the CD8
+
 T cell 
population, as a percentage of total lymphocytes, was increased as was the amount of 
SIINFEKL-tetramer positive cells (Figure 9a, b).  In the liver, the majority of infiltrating 
T cells were transgene-specific when TLR9 was given, however since the number CFSE 
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positive cells was reduced in this cohort, we hypothesize that by this point of the immune 
activation the transferred T cells may have undergone many rounds of division resulting 
in dilution of the CFSE to below our threshold for positive detection (Figure 9 b,c).  This 
indicates that most of the transferred cell population remaining had expanded as opposed 
to only a subset of that population suggesting that most of the T cells that survive migrate 
to the liver. 
Finally it was important to determine if TLR9 signaling in CD8
+
 T cells was 
responsible for immune activation.  C57Bl/6 or TLR9 KO mice were administered AAV8 
hOTCco-SIINFEKL.  Fourteen days later, mice were given OT-1 T cells and TLR9 
agonist.  In this experiment TLR9 KO mice that received the CD8
+
 T cells will only have 
signaling in the adoptively transferred cells.  We found that transaminase levels did not 
elevate in TLR9 -/- mice given both agonist and T cells (Figure 10 a).  GC and mRNA 
levels were similar to vector only control in treated TLR9 KO (Figure 10 b).  Taken 
together, these results demonstrate the need for TLR9 signaling extrinsic to the T cells 
that will become activated.  This is important as during gene delivery TLR9 signaling 
should occur only in cells transduced by the vector or potentially by the antigen 
presenting cells that take up vector particles.   
These results establish a method for investigating a cytotoxic T cell response to a 
mitochondrial targeted gene therapy of the liver.  We observed that it was necessary to 
have both a strong inflammatory event and transgene specific T cells.  Our evidence 
suggests that TLR9 could provide that inflammatory signaling, and as both other groups 
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and our own investigation into the humoral response has shown AAV provides a 
sufficient amount of DNA to initiate such a response (Zhu, Huang et al. 2009).  If we are 
able to either avoid or suppress this signaling we would anticipate a much reduced 
immune response to the transgene product.  An important question for the field would be 
how long does the vector DNA remain in endosomes after transduction and the likely 
hood that it could lead to inflammation in the months following gene therapy.  The 
requirement for having a pool of naïve antigen specific T cells also provides optimism as 
in the third chapter we describe a mechanism that could potentially reduce the number of 
these T cells from individuals with a PTC mutation. 
Tolerance to Epitopes C-Terminal of a PTC 
One guiding principal for the dangers of transgene-specific T cell activation is 
how the genotype of the afflicted individual can alter the outcome.  Specifically, that 
people with missense mutations that are expected to allow reduced or non-functional 
protein expression will retain tolerance to the transgene product as both negative 
selection and anergy should still be occurring; compared to those that lack expression of 
protein altogether whom we would assume lack those mechanisms for preventing an 
auto-immune response to gene therapy.  In our work on OTC we thought it was important 
to explore the potential effects of a patient's genotype on the outcome of gene therapy as 
most individuals in OTC tend to have private mutations as opposed to some disorders that 
have a single mutation predominate, such as the delta 508 CFTR mutation in cystic 
fibrosis.  A potential area of concern was related to missense mutations resulting in 
 105 
 
proteins that could aggregate or in some other way cause cellular stress in ways similar to 
the Z allele of ATAT (Carrell and Lomas 2002, Flotte, Trapnell et al. 2011).  In less 
extreme forms, misfolding can lead to endoplasmic reticulum stress releasing oxygen 
species, which could lead to a pre-inflammatory environment which could be prone to 
initiating an immune response upon AAV mediated gene therapy (Nakagawa and Yuan 
2000, Malhotra, Miao et al. 2008).  This would deviate from our understating that any 
specific missense mutation would not carry an increased risk of immune activation.  To 
investigate these potential effects we chose to create a panel of hOTCco-SIINFEKL 
constructs that contained missense mutations or nonsense mutations originally discovered 
in individuals with OTC deficiency (Table 1).  In our initial screen of these mutants we 
found that only one of our selected missense mutants had increased antigen presentation 
as measured by IFN-ɣ ELISPOT, which was anticipated since this category of mutation 
should not interfere with translation and the mutation, R26Q, occurs in the leader 
sequence of OTC potentially interfering with biogenesis. (Grompe, Muzny et al. 1989) 
(Figure 11 a, b). Of noted interest were the results obtained from our nonsense mutant 
constructs, where each was capable of expressing antigen that is C-terminal to the PTC.   
This result contrasted our assumed model where antigen presentation should not 
occur, and indicated that expression of epitopes in spite of a PTC could occur and that 
potential exists for tolerance either peripheral or central to transpire in individuals with 
nonsense mutations (Figure 25 a).  The source of antigens presented on MHC has been 
contested in the past with two competing theories; one holds that antigens presented are 
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primarily from fully formed proteins degraded by the proteasome as part of the natural 
turnover cycle (Colbert, Farfan-Arribas et al. 2013) the second states that the primary 
reservoir of epitopes are generated from DRiPS, defective ribosomal products that 
include early terminated peptides chains (Yewdell, Anton et al. 1996, Dolan, Li et al. 
2010, Dolan, Li et al. 2011).  In our model, it is possible that one or both are occurring, 
read-through of the PTC by incorporation of a cognate tRNA would allow for continuous 
synthesis of our constructs with the finished protein being degraded by turnover 
processes (Goodenough, Robinson et al. 2014), another option is that translation is being 
initiated downstream of the PTC creating peptide chains that are immediately sent to the 
proteasome for degradations (Bazykin and Kochetov 2011, Kochetov, Prayaga et al. 
2013) (Figure 25 b, c).  Our investigation required the production of several more 
constructs to interrogate these hypotheses and we took advantage of inducing PTC at 
different location or in volume.  Our in vitro work demonstrated that read-through was 
unlikely to be occurring, our construct with three mutations, CLP109-111X, did not have 
any decrease in T cell activation compared to a single stop codon at position 109 and we 
believe it unlikely that cognate tRNA incorporation would occur at the same rate in both 
instances (Figure 12 a). Conversely, mutation K353X is one removed from the start of the 
SIINFEKL epitope and effectively shut down expression of the peptides measured by our 
T cell assay.  We believe this demonstrates that by having more gene sequence between 
the PTC and epitope one increases the chance of an alternative start site initiating 
translation, whereas if read-through we the dominant cause of expression position would 
have less of an effect.  Finally using a +1 frame shift mutation at P110 we show that C-
 107 
 
terminal expression occurs, this is important as the frame shift generates 17 PTC, in 
addition even if all stop codons were read-through the downstream product would be out 
of frame and SIINFEKL would never be translated, therefore we conclude that enough 
translation events to generate a pool of antigens must begin C-terminal to the PTC  
(Figure 12 a). 
We attempted to identify the site of alternative translation initiation and to 
accomplish this we created two panels of constructs, one where each methionine down-
stream of the C109X mutation was substituted with a stop codon, and a second where 
each methionine is changed to an arginine.  Our results showed that alternative initiation 
did not require an AUG site as all our Met-Arg substitution constructs did not prevent C-
terminal expression (Figure 12 c). From our Met-Stop mutants we saw that only the final 
mutation M338X inhibited translation, indicating that either it or the M335X mutation 
were involved in some capacity to start translation as the intervening codons are not 
common alternative start codons such as CUG or GUG (Figure 12 b) (Starck, Jiang et al. 
2012).  Taken together we hypothesize that multiple codons contribute to translation 
initiation including both canonical and non-canonical start codons. 
While these observations are interesting with respect to antigen presentation and 
offer more evidence for the importance of the DRiP theory to explain the source of 
antigen presentation, we think that in the context of gene therapy it could be very 
important to considering how we think individual mutations can influence the outcome of 
gene therapy.  To determine if these phenomena occur in an animal model, we packaged 
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the C109X construct into an Ad5 vector and injected into mice. We observed an immune 
activation against SIINFEKL as measured by the INF-ɣ ELISPOT assay against both the 
WT and mutant gene containing vectors indicating that epitopes C-terminal to a PTC 
were expressed and presented on MHC class I to CD8+ T cells (Figure 14).   
Induction of tolerance to the transgene product is an important potential outcome 
of our work.  If antigen presentation is occurring even in individuals with a PTC or other 
null mutation, tolerance could still be maintained if alternative translation occurs at a 
significant enough rate to either create central tolerance and thereby deplete the body of 
transgene specific T cells or by peripheral tolerance inducing anergy in transgene specific 
T cells.  To explore these possibilities we used a model of peripheral tolerance and 
anergy where expression of an antigen from the liver will induce tolerance to antigens in 
the transgene product by exposure of naïve T cells to their epitopes without major 
inflammation signals (Lin, Hensley et al. 2007).  To determine if tolerance to epitopes C-
terminal to a PTC could induce tolerance similar to normal protein we created AAV8 
vectors containing hOTCco-SIINFEKL constructs with stop codon mutations.  Mice were 
given the AAV vectors and then challenged with Ad5 hOTCco-SIINFEKL, followed by 
analysis by INF-ɣ ELISPOT assay.  The results showed that a successful reduction of 
SIINFEKL specific cells occurred, providing evidence that an individual with a PTC 
could still induce tolerance to their defective protein (Figure 15 a).  Next, we challenged 
a second cohort of mice with Ad5 OVA to prevent activation of hOTC specific CD4
+
 
CD25
+
 T-regulatory cells that can be induced by liver directed AAV gene transfer.  This 
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was important as OTC-specific T regulatory cells could have become active against N-
terminal OTC epitopes; by using Ad5 OVA to provide the SIINFEKL we avoided that 
possibility.  Again we showed that the PTC containing constructs reduce T cell activation 
and lower the amount of SIINFEKL specific T cells (Figure 15 a, b).   
Taken as a whole these studies provide insight into the source of antigen 
presented on MHC class 1 and the potential for tolerance to intracellular proteins that are 
expressed in the liver.  Our work provides strong evidence that a large contributor to the 
antigen pool comes from defective ribosomal products, specifically from peptides derived 
from start sites within the gene.  Peptide synthesis starting from internal start sites was 
sufficient to create the requisite amount of peptides to load onto MHC class 1 and present 
antigen, even with the possibility of mRNA degradation of mutant transcripts by 
nonsense mediated decay.  While other groups have observed presentation from peptides 
formed N-terminal to a PTC this is the first evidence that epitopes found downstream of a 
PTC could lead to T cell activation (Apcher, Daskalogianni et al. 2011).  A clinically 
relevant application is that antigen presentation of epitopes C-terminal to a PTC could 
allow for T cell tolerance to be generated to the defective gene’s product.  Based on these 
results we should reevaluate how individuals are chosen for clinical trials.  Patients that 
contain a PTC mutation in the defective gene should not be denied the opportunity to 
contribute to the advancement of gene therapy development and the potential of receiving 
a positive health outcome. 
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Anti-Transgene Antibodies 
The humoral response is the other major branch in the adaptive immune system 
and while it shares many systems with the cytotoxic response including assistance in 
activation via CD4+ T cell help it seems to have a different threshold for activation based 
results from pre-clinical models and enzyme replacement therapy (Nayak, Doerfler et al. 
2014, Hinderer, Bell et al. 2015, Doerfler, Todd et al. 2016).  We believed that immune 
activation was strongly tied to signaling through TLR9 an endosomal protein that 
becomes active upon binding unmethylated CpG motifs.  Signaling through TLR9 results 
in translocation of NF-Kb to the nuclease and up-regulation of pro-inflammatory genes, 
which could cause activation of antigen presenting cells and lead to an adaptive immune 
response.  AAV vector genome can provide unmethlyated CpG to TLR9 if the vector 
genome is released during its transition from the cell surface to the nucleus.  Previously 
we had investigated the importance of TLR9 signaling on the transduction of β-
glycosidase in mouse muscle and demonstrated that removing CpG motifs prevented loss 
of transduction due to T cell activation (Faust, Bell et al. 2013).  In a furtherance of that 
study we chose to investigate the impact of TLR9 signaling on gene therapy of MPS1 by 
transduction of the IDUA gene.  While not part of its normal biogenesis pathway, IDUA, 
can be secreted through Golgi transport and then taken back up by other cells due to its 
binding of mannose-6-phosphate, this allows for cross correction of the disease but also 
leaves it vulnerability to a humoral response (Huang, Wong et al. 1997).   
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To investigate the effect of TLR9 on the humoral response to IDUA we 
administered either C57Bl/6 mice or TLR9 KO mice with AAV9 vector containing the 
IDUA transgene.  Using three different cohorts we varied the promoters between groups 
to have two universal expressers (CB7, CMV) and one liver restricted expresser (TBG) 
(Figure 19).   These studies contribute two important findings, first we demonstrate that 
location of transgene expression has a great deal of impact on antibody formation with 
expression from liver peaking high and maintaining stable with no anti-transgene 
antibody generation compared to either universal expresser that peak and fall off 
presumable due to the corresponding rise in antibody titer.  The second finding was that 
without TLR9, mice could not mount a humoral response against the transgene product.  
To control for any B cell developmental differences in TLR9 KO mice we adoptively 
transferred both KO mice B cells and C57Bl/6 B cells to µMT mice which lack B cells 
due to loss of the IgM gene.  In both groups mice were capable of generating an antibody 
response that attenuated transgene expression indicating that the TLR9 KO B cells are 
comparable functional to WT mice (Figure 21).  We also confirmed that TLR9 signaling 
is vital to T cell activation by measuring IFN- ɣ ELISPOT of splenocytes following 
AAV9.IDUA transduction (Figure 20).  Together these results demonstrate a very 
important finding that the unmethylated AAV vector genome is not only the primary 
immunogenic material, but that TLR9 signal is necessary to generate a humoral response.  
It would be invaluable to the field if the of AAV if vector immunogenicity could be 
decreased, and our lab has had experience in CpG depletion of AAV vectors a method 
that is possible due to multiple codons available for the same tRNA. 
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 We systematically removed all CpG motifs from the IDUA gene while still 
retaining the same protein coding sequence.  For the poly A and promoter we used ones 
previously generated to be CpG less as both CMV and CB7 contain large CpG islands 
and their removal would most likely impair functionality of the promoter (Faust, Bell et 
al. 2013).  C57Bl/6 mice were administered AAV9.Ef1α.IDUA with either WT or CpG 
depleted IDUA gene sequence and our results showed that there was no difference 
between the two groups in either antibody titer or transgene activity (Figure 22 a, b).  In 
addition T cell activation against the transgene as measured by the INF-ɣ ELISPOT assay 
did not shown any meaningful differences.  Interestingly, unlike other universal 
promoters the EF1α vector resulted in a lower antibody titer and maintained stable levels 
of transgene activity. One possible explanation for this and the results as a whole is that 
the CpG islands in CMV and CB7 were more important for TLR9 activation than the 
CpG motifs found in IDUA.  This may mean that using promoters with lower CpG 
content and avoidance of CpG islands could be as effective as CpG depletion. 
 The location of transgene expression has also been noted to have an influence on 
the immune response to transgene expression. Most of the research to date has been 
focused on the ability of the liver to “tolerize” the body against a secreted product, less 
has been explored into which cell type of expression result in such antibody responses 
(Dobrzynski, Fitzgerald et al. 2006, Cao, Dobrzynski et al. 2007, Doerfler, Todd et al. 
2016).  As we observed in Chapter 4 anti-IDUA antibody responses could be modulated 
by the promoter used to drive expression, with more universal promoters allowing for 
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robust formation of anti-transgene antibodies.  To determine if expression from the liver 
was able to tolerize or that expression from other locations would overwhelm any T 
regulatory cell activation and push the immune system toward a humoral response we 
treated mice with equal amounts of both TBG and CMV driven AAV9 IDUA vectors.  
From our results we observed a similar response to (Doerfler, Todd et al. 2016) where 
despite having a large dose of liver specific expression it seems that the driving force of 
anti-body formation is expression from non-liver tissues  (Figure 24 a).  One tissue group 
that we hypothesized was the most important for antibody formation to a secreted 
transgene delivered by AAV9 is the muscle as it is both highly transduced and capable of 
expressing MHC class II (Vandendriessche, Thorrez et al. 2007, Zincarelli, Soltys et al. 
2008) (Englund, Lindroos et al. 2001).  We injected mice with AAV9.CB7.IDUA vectors 
some of which contained a micro RNA site (miR206) that is targeted only in muscle 
(Greig, Peng et al. 2014) and observed that mice injected with the miR206 containing 
vectors had both lower anti-IDUA antibodies and higher long term expression.  This 
result is important as it demonstrates that expression from the muscle may be the most 
important transduction target that results in the generation of anti-transgene antibodies. In 
future work, if we can achieve cross correction with a transgene we may want to limit the 
organs of transduction to exclude the muscle or diminish expression from that location by 
inclusion of micro RNA sites. 
 These results describe the vital role TLR9 and location of transgene expression 
play in the generation of a humoral immune response to a transgene product.  As 
 114 
 
demonstrated in our knockout experiments TLR9 is both necessary and sufficient to 
activate B cell secretion of anti-IDUA antibodies, provided that transgene expression is 
not restricted to the liver.  One attempt to evade the TRL9 mediated B cell activation was 
CpG depletion of our transgene construct, our results show no improvement was made in 
avoiding antibody detection compared to our control.  We did observe that changing from 
a CpG rich CB7 promoter, to a CpG depleted EF1α promoter we had a dramatic effect on 
serum IDUA activity and antibody-formation, however the interpretation of this result is 
somewhat complicated by the fact that despite both being considered “universal 
expressers” there may be small difference in expression from different cell types that 
could impact on the result.  We further interrogated our observation and found that for 
AAV9 vectors, expression from the muscle was an important factor in formation of a 
robust anti-IDUA immune response.  This has important implications for delivery of gene 
therapy where we would surmise that expression of secreted transgene would be more 
tolerated if it only originated from the liver.  I would recommend that for a therapy where 
a cross correction strategy is viable one should either restrict expression to the liver, or 
design the vector construct as to avoid transgene expression from skeletal muscle cells.   
Final Remarks  
Throughout this dissertation, my extensive investigation of the adaptive immune 
response to transgene products following AAV transduction have given us important 
insight into the factors which influence the outcome.  I determined influential host factors 
that are required for adaptive immune activation, giving us the ability to design better 
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AAV vector constructs in hopes of reducing the likelihood of an adverse immune 
response in patients. My hope is that my research will contribute to the safety and 
effectiveness of the AAV gene therapy delivery platform and will allow for a broader 
group of individuals to be candidates for treatment. 
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Figure 25  Model of antigen presentation in PTC containing genes 
 
Generation of epitopes from a gene first requires transcription of the gene into messenger 
RNA and the translation of the mRNA into a polypeptide.  (A) The classical model of 
antigen presentation in genes that contain a PTC is that epitopes C-terminal to the stop 
codon will not be generated and thus not presented as antigen.  (B) One model that allows 
for antigen presentation of these C-terminal epitopes is by initiation of protein synthesis 
downstream of the PTC allowing for generation of the antigen.  (C) A second model for 
antigen presentation of epitopes C-terminal to a PTC is during translation when a stop 
codon would incorporate a stop-tRNA into the peptide sequence, instead a cognate tRNA 
would be put in place and allow for continued synthesis of the protein.  
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